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Variations in the gene CACNA1C, which encodes the protein Cav1.2, has been 
identified as a risk factor for a number of neuropsychiatric disorders including major 
depressive disorder, schizophrenia, bipolar disorder, attention deficit hyperactivity 
disorder and autism spectrum disorder. Follow up studies revealed that an intronic single 
nucleotide polymorphism (SNP) rs1006737 of CACNA1C can lead to both higher or lower 
CACNA1C expression as well as altered Cav1.2 function in neurons. Therefore, in this 
dissertation, I use cacna1c transgenic mouse models that harbor Cav1.2 knockout in 
specific brain regions and cell types to study the role of the L-type calcium channel, Cav1.2 
in neuropsychiatric disorders.  
 Using a transgenic mouse model, I discovered that Cav1.2 in the glutamatergic 
neurons of the forebrain regulate anxiety-like behaviors in mice. Using stereotaxic 
delivery of virus mediated gene transfer, I further showed that Cav1.2 in the 
glutamatergic neurons of the prefrontal cortex within the forebrain regulates anxiety-like 
behaviors in mice.  
 I also report a role for Cav1.2 in regulating depressive-like behaviors via 
Regulated in Development and DNA Damage (Redd1) in the prefrontal cortex. More 
specifically, Cav1.2 in non-glutamatergic neurons of the prefrontal cortex was found to 
modulate depressive-like behaviors in mice. 
  Since hippocampal adult neurogenesis is a process that has been associated with 
anxiety and depression, I studied the role of Cav1.2 in this process.  I found that Cav1.2, 
but not Cav1.3, is necessary for the survival, but not proliferation, of new born neuronal 
progenitor cells.  
 Since carriers of the SNP rs1006737 have been shown to have deficits in reward 
response, and drug addiction is so often co-morbid with anxiety and depression, I studied 
the role of Cav1.2 in cocaine addiction using the cocaine conditioned place preference 
behavioral paradigm. I found that Cav1.2 in the hippocampus is required for the normal 
decay of cocaine-context association memories following a long-term withdrawal from 
cocaine. I discovered that decreased Cav1.2 in the hippocampus leads to the preferential 
activation of the calcium calmodulin kinase pathway and increased phosphorylation of 
nuclear factor of activated T-cells (NFATc) in the nucleus accumbens, which underlies 
the maintenance or decay of cocaine-context association memories by Cav1.2.   
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Chapter 1: Introduction 
One of the most significant findings in the field of voltage-gated L-type 
calcium channel (LTCC) research in recent years is that in the largest human 
neuropsychiatric genetic study to date, CACNA1C, the gene that encodes for the 
Cav1.2 protein, was identified as one of only two genes and one of only four identified 
genomic loci to be a common risk factor for five major neuropsychiatric disorders; 
major depressive disorder, bipolar disorder, schizophrenia, autism spectrum disorder 
and attention deficit hyperactivity disorder (ADHD) (1). In previous studies, multiple 
different genes have been implicated as risk factors in the highly complicated 
landscape of neuropsychiatric disorders. The significance of the Lancet (2013) study 
however, is that it has identified CACNA1C as a common risk factor in multiple and 
across diverse neuropsychiatric disorders suggesting that CACNA1C may underlie 
pathological mechanisms and behaviors common across these disorders. It is truly 
exciting to consider that CACNA1C, which functions to regulate activity-dependent 
gene transcription during early development and in brain plasticity-dependent events, 
may be a master regulatory gene that is commonly dysregulated across an array of 
neuropsychiatric diseases, thereby altering a host of other downstream genes and 
transcriptional programs to ultimately cause functional abnormalities that underlies 
pathological mechanisms and behaviors in a variety of neuropsychiatric diseases. This 
highlights the urgency to further characterize the role of CACNA1C in common major 
underlying symptoms of neuropsychiatric disorders such as anxiety, depression and 
reward responses. A more thorough understanding of the role of CACNA1C and its 
downstream molecular mechanisms that underlie these symptoms will not only 
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provide the field with a deeper appreciation of the role of CACNA1C in 
neuropsychiatric disorders, but also provide potential novel targets for more effective 
treatment for these devastating diseases. In this dissertation, I use a multidisciplinary 
approach in preclinical mouse models to investigate the role of Cav1.2 and its 
downstream signaling molecules in specific brain regions in anxiety, depressive 
behaviors and reward responses.  
 
Voltage gated L-type calcium channels  
Voltage gated calcium channels (VGCCs) are key proteins that mediate Ca2+ 
entry into cells in response to membrane depolarization.  VGCCs are classified into 
different types based on their pharmacological and biophysical properties (Table 1); 
(2, 3).  Members of the L-type VGCC (LTCC) subfamily are high voltage-activated 
Ca2+ channels and are sensitive to dihydropyridines. One or more LTCC isoform is 
expressed in essentially all electrically excitable cells (4). There are four LTCC 
isoforms; Cav1.1, Cav1.2, Cav1.3 and Cav1.4 that form the primary Ca
2+ pore for Ca2+ 
influx into the cell (Figure 1).  In addition, they complex with auxiliary , 2-, and  
subunits (Figure 1) that regulate the functional properties of the Cav subunit.  Cav1.2, 
encoded by the gene CACNA1C, and Cav1.3, encoded by CACNA1D, are the 
predominant LTCC isoforms found in neurons (5). These neuronal LTCCs are 
important for regulating activity dependent gene expression, cell survival and synaptic 
plasticity (6-8).  
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Brain specific L-type calcium channels: Cav1.2 and Cav1.3 
Cav1.2 and Cav1.3 have different functions and distribution in the brain (9-12). 
Cav1.2 and Cav1.3 differentially activate Ca
2+ signaling cascades due to their distinct 
biophysical properties and distinct signaling complexes that they associate with (13-
16). Cav1.2 is the predominant LTCC in the brain, and accounts for about 90% of all 
LTCCs in the brain (17, 18). Cav1.2 and Cav1.3 are both present in overlapping brain 
regions such as the hippocampus, cortex, striatum, and cerebellum, but their 
subcellular distribution differs: Cav1.2 is mainly present in postsynaptic dendrites and 
Cav1.3 in cell bodies (17). In midbrain structures such as the ventral tegmental area, 
Cav1.3 is the predominant LTCC isoform (12). 
To date, no pharmacological agent specific for Cav1.2 or Cav1.3 exists (5). 
Therefore currently, transgenic animal models and focal genetic manipulations for 
either the cacna1c or cacna1d gene is the only way to study the specific role of Cav1.2 
or Cav1.3 in neuronal function and behavior.  
 
CACNA1C genetic variants and neuropsychiatric disorders 
In humans, genome-wide association studies (GWAS) have linked multiple 
single nucleotide polymorphisms (SNPs) in the CACNA1C gene to neuropsychiatric 
disorders. Several SNPs and in particular SNP rs1006737 has been widely reproduced 
and strongly associated to bipolar disorder (19), major depressive disorder (20, 21) 
and schizophrenia (20, 22).  Clinical and brain imaging studies have reported altered 
brain volume (23, 24), connectivity (25), and cognitive performance (24, 26-28) 
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further underscoring the functional contribution of CACNA1C to the neuropathology 
underlying neuropsychiatric disorders.  
The majority of identified CACNA1C SNPs are present within non-coding 
regions (intronic, 5’ and 3’ untranslated regions). Recent studies have revealed that 
non-coding SNPs can result in both an increase or decrease of CACNA1C mRNA, 
suggesting that gain or loss of Cav1.2 function can be detrimental (29, 30).  Using 
induced pluripotent stem cell (iPSC)-derived neurons from rs1006737 carriers, 
Yoshimizu et al found higher CACNA1C mRNA and LTCC current (30).  A similar 
increase in mRNA was found in the postmortem brains of rs2006737 carriers by Bigos 
et al (31).  In contrast, the same SNP was associated with lower CACNA1C levels in 
postmortem cerebellum with no difference in the parietal cortex (32).  Another study 
examined a schizophrenia risk CACNA1C SNP in human iPSC-derived neurons, 
postmortem brain and in vitro cell lines, and found lower CACNA1C expression, 
suggesting brain region specific, as well as potentially neuron subtype-specific 
regulation (29).  
The CACNA1C risk allele was found to be associated with increased brain 
stem volume (33), smaller putamen (23) and decreased activity in the right inferior 
parietal lobe and medial frontal gyrus (34).  
 
L-type Ca2+ channels and anxiety 
Since anxiety is a prominent common underlying symptom in all five of the 
neuropsychiatric disorders that the CACNA1C risk allele has been linked to, I 
investigated the role of cacna1c in anxiety-like behaviors in mice. In Chapter 2, I 
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explore the role of cacna1c in select brain regions that have been implicated in 
regulating anxiety and I explore the role of cacna1c in specific cell-types within focal 
brain regions. 
Several human (35-38) and rodent (39, 40) studies establish the prefrontal 
cortex (PFC) as playing a critical role in emotional states such as anxiety.  The role of 
PFC in regulating fear extinction, another way to measure anxiety-like behavior in 
rodents is also well established (41). Therefore, I first focused on the role of cacna1c 
in the PFC in anxiety. 
The PFC receives excitatory inputs from the hippocampus (HPC), (42) another 
important brain region suggested to be involved in regulating anxiety behaviors (43-
45). Furthermore, in humans the CACNA1C neuropsychiatric risk variant has been 
associated with altered connectivity between the PFC and HPC (46). Therefore, I 
further investigated the consequences of cacna1c KO in the HPC to see whether 
elimination of Cav1.2 in the HPC can recapitulate the behavioral phenotype observed 
in the PFC Cav1.2 knockout mice by altering the HPC-PFC circuitry. 
 
L-type Ca2+ channels and depression 
The CACNA1C risk allele has been most strongly associated with bipolar 
disorder (19, 47), which includes clinical manifestations of depression and mania; and 
also with unipolar depression (48). The risk variant has also been associated with 
altered neural processing in major depressive disorder (26). Further, carriers of the 
CACNA1C risk allele show altered neural activity in the limbic system, which includes 
the PFC, during emotional processing (49). It is now well established from human and 
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rodent studies that the PFC is a critical brain region involved in regulating affect, 
including depression (50-52). 
  Preclinical studies have found that intraperitoneal (i.p.) injection of a  
dihydropyridine LTCC blocker resulted in an anti-depressive phenotype as measured 
by the forced swim test (FST) (53), whereas i.p. injection of the dihydropyridine 
LTCC agonist BayK 8644, resulted in a depressive-like phenotype (54). Constitutive 
cacna1c heterozygous mice (HET) also show an anti-depressive like phenotype as 
measured by FST and by tail suspension test (55).  
Since it is established that Cav1.2 regulates depressive-like behaviors in mice 
and that the PFC is a critical brain region in regulating these behaviors, I investigated 
the role of Cav1.2 and its downstream molecular mechanisms that have also been 
implicated in depression, within the PFC. I also explored the role of Cav1.2 in the HPC 
in depressive behaviors, as this brain region has projections to the PFC (42), has also 
been implicated in regulation of emotional behaviors (43, 56), and showed altered 
activity during emotional processing that was associated with the CACNA1C risk 
allele (31).   
 
L-type Ca2+ channels in adult hippocampal neurogenesis 
Many rodent models of mood disorders have been shown to have deficits in 
adult hippocampal neurogenesis (HPC NG) (57, 58), and drugs that alleviate 
symptoms of anxiety and depression also improve these HPC NG deficits (57, 58). 
Disrupting adult HPC NG has been shown to produce anxiety (59) and depression (60, 
61) in some cases and not in others (58), which underscores the complexity of adult 
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HPC NG and its involvement in mood disorders. Interestingly, in vitro 
pharmacological studies using dihydropyridines to block LTCCs have found that they 
are involved in adult HPC NG, (62). As LTCCs are also implicated in anxiety and 
depressive behaviors, and adult HPC NG has been involved in these same behaviors, I 
investigated whether LTCCs regulate adult HPC NG in vivo by using transgenic 
mouse models and site-specific virus mediated deletion of cacna1c (Cav1.2) or 
cacna1d (Cav1.3).  
 
CACNA1C and brain reward systems 
Altered reward brain circuitry and responsiveness is another common, co-
morbid condition often associated with various psychiatric disorders (63, 64). Many 
studies reveal the convergence of the pathways and molecular mechanisms involved in 
mood disorders and reward systems (41, 65, 66). Recently, human carriers of the 
bipolar disorder and schizophrenia-associated CACNA1C SNP rs1006737 were found 
to be associated with decreased reward responsiveness compared to non-carriers (67, 
68). Importantly, drug abuse is commonly found to be co-morbid with mood disorders 
(63, 68-70). Patients with anxiety disorders for example, were shown to have higher 
likelihood of cocaine use even after correcting for other contributing factors such as 
socio-economical and other co-morbid disorders (71, 72). 
 
L-type Ca2+ channels and cocaine addiction 
We and others have shown that LTCCs are involved in the rewarding effects of 
cocaine (73, 74). Specifically, only Cav1.2, and not Cav1.3, is up-regulated by repeated 
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cocaine, especially in the PFC (68, 75), a brain region critically implicated in the long-
lasting effects of cocaine. Other studies have shown that LTCCs are involved in 
cocaine seeking behavior (76, 77). Further, systemic LTCC antagonists attenuate 
cocaine conditioned place preference (CPP) (78, 79), whereas focal infusion of LTCC 
antagonist into the nucleus accumbens shell, a critical brain reward region, facilitates 
cocaine CPP (80), highlighting the different roles LTCCs can have on cocaine seeking 
behavior, based on their neuroanatomical location. 
Cocaine CPP is a simple, non-invasive procedure wherein animals are trained 
to associate a specific environment with the rewarding effects of a drug. When 
animals are allowed to freely explore the drug paired and non-drug paired 
environment, they prefer the drug-paired environment, indicating development of 
cocaine preference or CPP. The CPP protocol has been extended to include extinction 
and reinstatement of drug seeking, to explore mechanisms of drug craving and relapse 
(81-86). The conditioned response is thought to be relevant to human drug-seeking 
behavior and drug- and cue-induced relapse (84-86).  
 
L-type Ca2+ channels in maintenance of cocaine memory following long-term 
withdrawal from cocaine CPP 
Even after extinction of cocaine seeking behaviors, relapse is not uncommon in 
cocaine addiction. Preventing relapse is a main goal of cocaine addiction treatment. 
One of the biggest obstacles in preventing relapse, or reinstatement in rodent models, 
is the potent associative learning that is established between the effects of cocaine and 
the drug-taking context. These associative memories can be so strong that even after 
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years of withdrawal from drug, just the context without the presence of cocaine, can 
be enough to trigger drug-seeking behavior  (81). These long-lasting context-cocaine 
association memories are thought to be regulated by cocaine induced persistent 
changes in gene transcription in the brain (87), such as those regulated by LTCC (88). 
It is well established that the HPC is critically involved in regulating context-
reward memories (89-92). Interestingly, LTCCs have been implicated in long-term 
retention of spatial memory, another type of HPC dependent memory (93). Mice 
harboring forebrain specific knockout of Cav1.2 have been shown to have deficits in 
specifically the retrieval of long-term spatial memories (94). Furthermore, studies 
report an increase in Cav1.2 signaling in the HPC during aging, potentially 
contributing to the cognitive deficits such as forgetfulness, commonly associated with 
aging (95, 96). Importantly, carriers of the CACNA1C risk allele display abnormal 
reward response (67). Therefore, in Chapter 6, I investigated the role of Cav1.2 and its 
downstream molecules in the HPC in the maintenance of cocaine-context association 
memories following long-term withdrawal from drug.  
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Chapter 2: Forebrain elimination of cacna1c mediates anxiety-like behavior in 
mice*  
 
Introduction 
The CACNA1C gene encoding the Cav1.2 subunit of the L-type calcium 
channel (LTCC) has emerged as a new candidate gene for neuropsychiatric disease, 
including bipolar disorder, major depression, schizophrenia, autism and attention 
deficit hyperactivity disorder (1-4).  We report that global haploinsufficiency, 
forebrain-specific elimination, and prefrontal cortex (PFC)-specific knockdown of 
cacna1c in mice all increase anxiety-related behavior, without affecting compulsive 
behavior, a prominent component of the forms of neuropsychiatric disease in which 
aberrations in CACNA1C have been implicated.   
 
Methods and Materials 
Animals 
Male C57BL/6 mice (Jackson Laboratories, Bar Harbor, Maine), constitutive cacna1c 
HETs (5), and forebrain-cacna1c cKO and their respective WTs were 8-10 weeks old 
at the start of the experiments. For the grooming behavioral assay, 3-month old mice 
were used.  Forebrain-cacna1c cKO mice were generated by crossing homozygous 
cacna1c floxed mice (cacna1cfl/fl) (5); with mice expressing Cre recombinase under  
 
* A. S. Lee et al., Forebrain elimination of cacna1c mediates anxiety-like behavior in 
mice. Mol Psychiatry 17, 1054-1055 (2012). 
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the control of the alpha-CaMK2 promoter (CaMK2-Cre).  The CaMK2alpha-Cre T29-
1 line from Jackson Laboratories was used.  In this line, Cre expression is activated at 
postnatal day 18, thereby circumventing developmental compensatory adaptations.  
HETs and forebrain-cacna1c cKO were indistinguishable from WTs in weight, 
development and general health.  To generate region-specific deletion of cacna1c, 
AAV-Cre virus was stereotaxically delivered into the brain of homozygous cacna1cfl/fl 
mice.   Mice were provided food and water ad libitum.  Animals were maintained on a 
12-hr light/dark cycle (from 7 A.M. to 7 P.M.).  All procedures were conducted in 
accordance with the Weill Cornell Medical College and UT Southwestern Medical 
Center Institutional Animal Care and Use Committee rules.  
 
Quantitative real-time PCR (QPCR) 
Mice were euthanized by rapid decapitation and whole brains were rapidly dissected 
and frozen in isopentane at -40C.  Frozen brains were mounted in the coronal plane 
on a cryostat (Leica) and tissue punches from the specific regions listed in Table 1 
were obtained by unilateral (PFC, ventral tegmental area, cerebellum) or bilateral 
(hippocampus, basolateral amygdala, striatum, nucleus accumbens) as previously 
described (6).  RNA was isolated and Cav1.2 QPCR performed as previously 
described (6).  Briefly, tissue punches were processed for RNA using the RNeasy Mini 
Kit (QIAGEN) and cDNA was synthesized from purified RNA using the High 
Capacity RNA-to-cDNA kit (Applied Biosystems, Foster City, CA).  Cacna1c mRNA 
levels were measured using CACNA1C specific primers (QuantiTect Primer assay 
QT00150752; QIAGEN) on an ABI PRISM 7000 Sequence Detection System with 
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SYBR Green PCR Master Mix (Applied Biosystems).  Cycle threshold (Ct) values for 
target genes were normalized to the housekeeping gene -actin (primers as previously 
published) (7). Each experiment was performed in triplicate and values were averaged.  
 
Generation of region-specific elimination of cacna1c 
Stereotaxic delivery of AAV-Cre was performed as previously described (6).  Prior to 
surgery, mice were anesthetized with a ketamine (100 mg/ml) and xylazine (20 
mg/ml) cocktail, and mounted to a stereotaxic surgical unit (David Kopf Instruments, 
Tujunga, CA).  A midline incision was made atop the scalp, skin was retracted, the 
head was leveled based on bregma and lambda, and holes were formed through the 
skull using a 25 gauge needle.  AAV-GFP, AAV-Cre (Vector BioLabs, Philadelphia, 
PA) or AAV2/8-GFP , AAV2/8-CaMK2-Cre (University of Iowa, Iowa City, IA) were 
delivered into the PFC of cacna1cfl/fl mice with a 2.5µl, 30-gauge Hamilton syringe at 
a rate of 0.1µl/min (0.5µl/hemisphere).  The needle was left in place for an additional 
5 min after the infusion to ensure complete delivery of the virus.  Mice were allowed 
to recover for at least two weeks prior to behavioral testing to allow for maximal 
virus-mediated GFP expression and Cav1.2 knockdown. Stereotaxic coordinates for 
PFC (+2.0 AP, -2.5 DV, ±0.1ML) were adopted from Gourley et al., 2010 (8). A total 
of 1µl per mouse of AAV2/5-GFP or AAV2/5-Cre (University of Iowa, Iowa City) 
was injected into the vHPC using the coordinates: -3.5 AP, -4.2 DV, ±2.8 ML, at a 4° 
angle. A total of 0.4µl per mouse of AAV2/2-GFP or AAV2/2-Cre was injected into 
the dHPC using the coordinates: -1.4 AP, -2 DV, ±1.1ML at a 10° angle. 
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GFP immunohistochemistry 
GFP fluorescent immunohistochemistry was used to confirm injection placement.  
Upon completion of behavioral testing, mice were sacrificed and perfused with 4% 
paraformaldehyde (PFA). Brains were dissected and post-fixed overnight in 4% PFA 
followed by cryo-protection in 30% sucrose at 4C for at least 72 hours.  Forty µm 
sections spanning the PFC were obtained using a sliding microtome and incubated in 
anti-rabbit GFP (1:500) primary antibody for 24 hours at 4C.   The sections were 
rinsed in 0.1M phosphate-buffer (PB) and incubated with donkey anti-rabbit Cy2 
(1:500) antibody for 1 hour at room temperature.  Animals with improper bilateral 
injection placement were excluded from behavioral data analysis.   
 
Cav1.2 immunohistochemistry 
Fluorescent immunohistochemistry was used to confirm knockdown of Cav1.2. 
Cacna1cfl/fl mice that received infusions of AAV-GFP or AAV-Cre were deeply 
anesthetized with pentobarbital (150mg/kg, i.p.) and perfused as described in 
Beckerman and Glass, 2011 (9). Briefly, mice were transcardially perfused with 10ml 
of 2% Heparin in 0.9% saline followed by 40ml of 3.75% acrolein in 2% PFA in 0.1M 
PB, (pH 7.4), followed by at least 50ml of 2% PFA in 0.1M PB. Brains were then 
post-fixed in 2% PFA in 0.1M PB for at least 30 minutes prior to sectioning on a 
vibratome. Forty µm sections spanning the PFC were collected, rinsed with 0.1M PB 
and incubated in 1% NaBH4 for 30 minutes at room temperature to permeabilize the 
tissue.  Sections were thoroughly rinsed with 0.1M PB then blocked in 0.5% bovine 
serum albumin (BSA) in 0.1M PB with 0.3% triton.   
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For Cav1.2 immunohistochemistry, sections were incubated in anti-rabbit Cav1.2 
(1:5000) (Amy Lee, University of Iowa, Iowa City, IA) and anti-chicken GFP 
(1:3000) for 24hrs at room temperature and for an additional 72hrs at 4C.  Sections 
were rinsed with 0.1M PB and incubated with 1mg/ml biotinylated donkey anti-rabbit 
(Jackson Labs) and donkey anti-chicken Alexa-fluor 488 (1:300) for 1 hour at room 
temperature.  After another rinse, sections were incubated in horseradish peroxidase 
conjugated streptavidin (SA-HRP) (1:500) for 1 hour at room temperature,  rinsed 
again, and then incubated in Alexa Fluor 647 labeled tyramide (1:100) in 0.0015% 
H2O2 amplification buffer for 10 minutes at room temperature.  Sections were rinsed 
with 0.1M PB and fluorescence detected with a confocal microscope. 
 
Basal locomotor activity 
Horizontal locomotor activity was assessed by computer-assisted activity monitoring 
software (Med Associates) in a polycarbonate test chamber (27.3 cm x 27.3 cm) 
equipped with three infrared beam arrays.  Locomotor activity was measured as total 
distance traveled in centimeters.  For each test session, animals were placed in the 
chamber and recorded for 2 h without interruption.  
 
Open field test 
Mice were placed in a 38 cm x 54 cm Plexiglas open field arena and their activity was 
monitored for 10 min with a video tracking system using EthoVision software (Noldus 
Information Technology, Leesburg, VA).  Duration of time spent in the center of the 
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open field (13 x 28 cm) and frequency to enter the center of the open field were 
analyzed. 
 
Light and dark conflict test 
During testing, mice were placed in the light half of a polycarbonate (27.3 cm x 27.3 
cm) chamber, which consisted of transparent walls and bright illumination by an 
incandescent lamp (~650 lux).  An acrylic, opaque dark insert comprised the other half 
of the chamber.  This insert did not obstruct the path of infrared beams, and also 
contained a small opening (5.5 cm x 7 cm) that allowed the subject to traverse each 
side freely while being sufficiently small to minimize the amount of light from 
entering (~1 lux) the dark side.  Mice were allowed to freely explore the chamber for 
10 min.  The number of transitions to and from each side as well as the time spent in 
each respective compartment was analyzed by post-hoc analysis using Med Associates 
(St. Albans, VT) Activity Monitor software. 
 
Elevated plus maze 
Mice were placed in the center of a cross-shaped maze elevated 38 cm above the floor 
and consisting of two open and two closed arms (50 cm).  The behavior of the mice 
was then monitored for 5 min by a video tracking system.  Time spent in the open and 
closed arms was obtained using the EthoVision software. 
Grooming Assay 
Three-month old mice were habituated to the test chamber for 30 minutes and 
videotaped for 5 minutes to assess their baseline state.  Mice were then sprayed 3 
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times on the head with a handheld water spray bottle and videotaped for a 5-minute 
period of time.  Video clips were viewed and scored by independent and blinded 
investigators, and the amount of time spent grooming was recorded with a handheld 
stopwatch. 
 
Statistics 
 For all experiments, data was analyzed by a one-way or two-way ANOVA followed 
by the Bonferroni-Dunn post-hoc test.  A value of p ≤ 0.05 was considered to be 
statistically significant. Statview 4.5 software (SAS Institute Inc., Cary, NC) was used 
for all statistics.   
 
Results 
Constitutive cacna1c heterozygous mice (HET) were evaluated in three 
behavioral assays related to anxiety:  open field test, light-dark conflict test and 
elevated plus maze (EPM).  HETs displayed anxiety-like behavior in the EPM (Figure 
1c), spending significantly less time exploring the open arms compared to wild-type 
littermate controls (WT) (F1,19 = 6.437; P < 0.05).  However, no differences were 
observed between HETs and WTs in the open field and light-dark conflict test, (Figure 
1a, 1b).  In the EPM test, we also observed a statistically significant effect of increased 
anxiety-like behavior in adult female HETs (Figure 1d) and adolescent male HETs 
(Figure 1e) compared to WTs. To more specifically investigate the function of 
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Figure 1. Cacna1c HET mice do not show differences in (a) open field and (b) 
light/dark as compared to WT mice. (n=11-16 per group). (c) Cacna1c HET 
(HET n=10; WT n=11), (main effect of genotype, F
1,19 
= 6.437; P < 0.05), **P 
< 0.01 (d) Adult female cacna1c HET (HET n =8; WT n = 11), (main effect of 
genotype, F
1,17 
= 4.673; P < 0.05). *P <  0.05. and (e) adolescent male cacna1c 
HET (HET n=8; WT n=9) show increased anxiety-like behavior as reflected by 
decreased time in the open arm of the EPM, compared to WT littermates, (main 
effect of genotype, F
1,15 
= 7.638; P < 0.05).*P <  0.05. 
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cacna1c in the brain, we generated forebrain-specific conditional cacna1c-deficient 
mice (forebrain-cacna1c cKO) by crossing cacna1c-floxed mice with mice harboring 
alphaCaM Kinase 2 (CaMK2) promoter-driven expression of Cre recombinase.  
Relative to WTs, this strategy achieved approximately 70% elimination of cacna1c 
mRNA in the hippocampus, PFC, basolateral amygdala, striatum and nucleus 
accumbens, as assessed by quantitative PCR (Table 1).  Cacna1c mRNA levels were 
unaffected in the ventral tegmental area and cerebellum.  With this greater reduction in 
cacna1c in forebrain than could be achieved in HETs, significantly increased anxiety-
like behavior was observed across all three behavioral assay. In the open field test, 
forebrain-cacna1c cKO mice spent less time exploring the center of the chamber 
compared to WTs (Figure 2a, F1,16 = 5.588; p < 0.05).  In the light-dark conflict test, 
forebrain-cacna1c cKO mice spent significantly less time in the brightly lit side 
compared to WTs (Figure  2b, F1,16 = 6.544; p < 0.05). In EPM, forebrain-cacna1c 
cKO mice spent significantly less time exploring the open arms compared to WTs 
(Figure 2c, F1,16 = 68.587; P < 0.0001).  Thus knockout of cacna1c in the CaMK2 
expressing neurons of the forebrain results in anxiety-like behavior. 
 Clinically, anxiety is often accompanied by compulsive behavior, such as in 
obsessive-compulsive disorder (OCD) in which patients seek alleviation from 
recurrent bouts of anxiety-inducing intrusive thoughts by engaging in compulsively 
repetitive behaviors.  Experimental models for OCD, such as SAPAP3 (10) or 
SLITRK5 (11) deficient mice, display pathologically high compulsive grooming that is 
readily quantified by the spray-induced grooming test.  Compared to respective  
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WTs, we did not observe elevated grooming in either HETs (Figure 3a) or forebrain-
cacna1c cKO mice (Figure 3b).  Thus, the form of anxiety associated with cacna1c 
function is distinct from that associated with OCD-spectrum illnesses. 
Some genetic variations in CACNA1C have been associated with altered PFC 
function (12-14) in neuropsychiatric disease, so we next generated focal elimination of 
cacna1c in the PFC with adeno-associated viral (AAV) vector-expressing Cre 
recombinase (AAV-Cre) (6).  AAV-Cre was stereotaxically delivered bilaterally into 
the PFC of cacna1cfl/fl mice (Figure 4a), and regional elimination of Cav1.2 was 
immunohistochemically confirmed (Figure 4b).   Following elimination of cacna1c in 
the PFC, mice showed no differences in basal locomotor activity compared to AAV-
GFP control injected mice (Figure 4c).  However, selective elimination of cacna1c in 
the PFC was associated with less time spent exploring open arms of the EPM, 
compared to control AAV-GFP injected mice (Figure 4d, F1,16 = 5.477; p < 0.05).  To 
evaluate the specificity of PFC cacna1c knockout in mediating anxiety, we used AAV 
expressing cacna1d siRNA (6) to selectively eliminate cacna1d in the PFC, the other 
LTCC isoform expressed in brain.  Selective knockdown of cacna1d in the PFC had 
no effect on locomotor behavior (Figure 5a) or time spent in open arms in the EPM 
(Figure 5b). 
To evaluate the contributing cell type within the PFC, we next generated a 
focal knockout of cacana1c in only the glutamatergic neurons of the PFC using AAV-
CaMK2-Cre (University of Iowa, Iowa City). Mice harboring knockout of cacna1c in 
glutamatergic neurons of the PFC showed increased anxiety-like phenotype as 
measured by decreased time spent in the open arms in the EPM test (Figure 6). Thus, 
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knockout of cacna1c in the glutamatergic neurons of the PFC results in anxiety-like 
behavior.  
The hippocampus (HPC) is another brain region that is mediating anxiety-
related phenotypes.  Lesion studies (15, 16) and more recently, optogenetic studies 
(17) identify the HPC, and in particular the ventral hippocampus (vHPC) as being 
involved in anxiety-like behaviors. The dorsal hippocampus (dHPC) on the other 
hand, has been attributed to cognitive processes such as spatial learning (17, 18). The 
vHPC, unlike the dHPC, sends glutamatergic projections to the PFC (19, 20) and the 
two regions show synchronous activity which increases with anxiety (21). Therefore, 
we next tested the role of cacna1c in the vHPC in mediating anxiety-like behavior.  
We generated focal knockout of cacna1c in the vHPC with AAV-Cre (Figure 7a). As 
a control region, we also generated focal knockout of cacna1c in the dHPC (Figure 
8a). Neither the vHPC nor the dHPC cacna1c KO mice showed any differences in the 
open field test, light-dark conflict test, or EPM (vHPC: Figure 7b-d, dHPC: Figure 8b-
d).  Thus, knockout of cacna1c in the vHPC or dHPC has no effect on anxiety-like 
behavior.   
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Discussion 
In summary, we report here the first direct evidence for a role of forebrain 
cacna1c in regulating anxiety.   Mice harboring forebrain-specific elimination of 
cacna1c may thus provide a useful tool for studying the pathophysiology of anxiety in 
forms of neuropsychiatric diseases in which CACNA1C in involved. Furthermore, 
although the anxiety in the forebrain-cacna1c cKO may rise from developmental 
compensatory changes from lacking cacna1c from around P18, we showed that 
knockout of cacna1c, and not cacna1d, in the adult PFC, and specifically in 
glutamatergic PFC neurons, is sufficient to replicate the anxiety phenotype. We also 
find that cacna1c elimination in the vHPC and dHPC does not affect anxiety-like 
behaviors. Thus, these findings demonstrate that dysregulation of Cav1.2 in the PFC 
and not the HPC, is involved in regulating anxiety-like behaviors.  
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Chapter 3: Cacna1c in the prefrontal cortex regulates depressive-like behavior 
via REDD1. 
 
Introduction 
Depression affects more than 350 million people and is the leading cause of 
disability worldwide (1). Not only does depression manifest as major depressive 
disorder, it is also a major component of other neuropsychiatric disorders such as 
bipolar disorder and schizophrenia (2). Despite its current and rising prevalence, the 
etiology of depression still remains largely unknown.  
The largest genome wide association study to date has identified single 
nucleotide polymorphisms (SNP) in the CACNA1C gene as a common risk variant 
across major depressive disorder, bipolar disorder, and schizophrenia (3). Constitutive 
cacna1c heterozygous mice (HET), that have global 50% knockdown of the Cav1.2 
protein that cacna1c encodes, have been shown to display an anti-depressive 
phenotype (4), suggesting that this protein is important for modulating depressive 
behaviors. However, the specific brain regions, the specific cell types and downstream 
molecular mechanisms by which Cav1.2 channels may be modulating depressive-like 
behavior have yet to be identified.  
Depressed patients who are also carriers of a CACNA1C SNP show altered 
neural processing in the prefrontal cortical region compared to non-carrier depressed 
patients, suggesting that the genotype confers a functional consequence in the 
prefrontal cortical brain region (5). Depressed patients have been shown to have lower 
brain volume, smaller size and density of neurons (6, 7) and abnormal activity (8) in 
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the prefrontal cortex (PFC). Stimulation of the PFC in treatment resistant depressed 
patients (9, 10) and in mice susceptible to depressive behavior (11) has been shown to 
have antidepressant effects. The hippocampus (HPC), which receives input from and 
sends output to the PFC, has also been heavily implicated in the pathophysiology of 
depression (12-15). Lesion studies (16) and more recent optogenetic studies (17) 
identify the ventral hippocampus (vHPC) in particular, as another brain region 
critically involved in emotional behaviors. The dorsal hippocampus (dHPC) on the 
other hand, has been attributed to cognitive processes such as spatial learning (17). 
The vHPC, unlike the dHPC, sends glutamatergic projections to the PFC (18, 19) and 
the two regions show synchronous activity (20).  Interestingly, human imaging studies 
reveal that carriers of the CACNA1C SNP rs 1006737, a highly significant SNP linked 
to bipolar disorder, major depressive disorder, and schizophrenia (21, 22), show 
altered brain activity in the PFC and HPC (23-25) suggesting that Cav1.2 channels in 
these regions may underlie neuropathology relevant to depressive phenotypes.  
A recent molecular study has identified that, depressed patients have higher 
levels of the protein Regulated in Development and DNA damage responses 1 
(REDD1), in the PFC (26). REDD1 specifically in the PFC, has also been shown to 
regulate depressive-like behavior in rodent models of depression (26). Therefore, in 
this study we sought to test the hypothesis that Cav1.2 in the PFC and HPC modulate 
depressive-like behaviors in mice via regulation of REDD1. 
 
Methods and Materials 
Animals 
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Male C57BL/6 mice (Jackson Laboratories, Bar Harbor, Maine), constitutive cacna1c 
HETs (27) and homozygous cacna1c floxed mice (cacna1cfl/fl ) (27) were at least 8 
weeks old at the start of the experiments. HETs and cacna1cfl/fl  mice were 
indistinguishable from respective wildtype littermates (WT) in weight, development 
and general health. Animals were maintained on a 12-hr light/dark cycle (from 7 A.M. 
to 7 P.M.). Mice were provided food and water ad libitum. All procedures were 
conducted in accordance with the Weill Cornell Medical College Institutional Animal 
Care and Use Committee rules.  
 
Surgeries  
To generate region-specific deletion of cacna1c, AAV-Cre was stereotaxically 
delivered into the brain of cacna1cfl/fl mice. Stereotaxic delivery of AAV-Cre was 
performed as previously described (28).  Prior to surgery, mice were anesthetized with 
a ketamine (100 mg/ml) and xylazine (20 mg/ml) cocktail, and mounted to a 
stereotaxic surgical unit (David Kopf Instruments, Tujunga, CA).  A midline incision 
was made atop the scalp, skin was retracted, the head was leveled based on bregma 
and lambda, and holes were formed through the skull using a 25-gauge needle.  AAV-
GFP or AAV-Cre (Vector BioLabs, Philadelphia, PA) were delivered into the PFC of 
cacna1cfl/fl mice with a 2.5µl, 30-gauge Hamilton syringe at a rate of 0.1µl/min 
(0.5µl/hemisphere) (+2.0 AP, -2.5 DV, ±0.1ML).  A total of 1µl per mouse of 
AAV2/5-GFP or AAV2/5-Cre (University of Iowa, Iowa City) was injected into the 
vHPC using the coordinates: -3.5 AP, -4.2 DV, ±2.8 ML, at a 4° angle. A total of 
0.4µl per mouse of AAV2/2-GFP or AAV2/2-Cre was injected into the dHPC using 
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the coordinates: -1.4 AP, -2 DV, ±1.1ML at a 10° angle. The needle was left in place 
for an additional 5 min after the infusion to ensure complete delivery of the viral 
vector.  Mice were allowed to recover for at least two weeks prior to behavioral testing 
to allow for maximal virus-mediated GFP expression and Cav1.2 knockout (KO). 
AAV-Cav1.3 siRNA was generated as described in Schierberl et al. (29) and was used 
to create a focal knockdown (KD) of Cav1.3 in the PFC (0.5µl/hemisphere) (-2 AP, 
+1.6 ML, -1.8 DV at a 10° angle). AAV2/8-CaMKII-Cre (University of Iowa, Iowa 
City, IA) was used to generate Cav1.2 KO specifically in CaMKII expressing 
excitatory neurons in the PFC of cacna1cfl/fl mice (0.5µl/hemisphere) (AP: +1.8, ML: 
+1.3, DV: -2, at a 30° angle ). AAV-REDD1 was generated as described in Ota et al. 
(26) and was used to over-express REDD1 in the PFC of Cav1.2 HET mice 
(1.2µl/hemisphere) (+2.3 AP, +1.7 ML, -2.8 DV). Mice were allowed to recover for at 
least three weeks prior to behavioral testing to allow for maximal virus mediated 
Cav1.3 KD, CaMKII-specific Cav1.2 KO and REDD1 overexpression.  
 
Green Fluorescent Protein (GFP) immunohistochemistry 
GFP immunohistochemistry was used to confirm injection placement.  Upon 
completion of behavioral testing, mice were anesthetized with euthasol and 
transcardially perfused with 4% paraformaldehyde (PFA). Brains were dissected and 
post-fixed overnight in 4% PFA followed by cryo-protection in 30% sucrose at 4C 
for at least 72 hours.  Forty µm sections spanning the PFC were obtained using a 
sliding microtome and incubated in anti-chicken GFP (1:2500) primary antibody for 
24 hours at 4C.   The sections were rinsed in 0.1M phosphate-buffer (PB) and 
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incubated with anti-chicken peroxidase secondary (1:300) antibody for 1 hour at room 
temperature. GFP staining was detected using the 3, 3’-diaminobenzidine peroxidase 
substrate kit (Vector Laboratories). Animals with improper bilateral injection 
placement were excluded from behavioral data analysis.   
 
Sucrose preference 
Mice were single housed for the duration of the sucrose preference behavior. The 
water bottle from each cage was removed and replaced with two smaller bottles, one 
containing drinking water and the other containing 5% sucrose dissolved in drinking 
water. A hole was drilled into each small bottle, allowing the mice to lick the solution 
from the drilled hole. Body weights and the mass of water and sucrose consumption 
were monitored once a day, for 4 days. Sucrose preference was calculated as ((sucrose 
consumed (g) – water consumed (g))/(sucrose consumed (g) + water consumed 
(g)))x100.  Mice were group housed after the completion of the sucrose preference 
test. 
 
Forced Swim Test 
Mice were placed into a 2L beaker containing 1800ml of 26°C water, one at a time, 
for 10 minutes each. Each mouse was video recorded from the front of the beaker and 
their time spent mobile was scored by an experimenter blind to the conditions using 
the ButtonBox software (Behavioral Research Solutions).  
 
Western Immunoblotting 
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To examine levels of REDD1, brains were isolated and PFC was isolated from freshly 
dissected brains.  Synaptosomal fractions were isolated as previously described (30). 
Briefly, tissue was homogenized in 250µl of sucrose/HEPES buffer in a glass dounce 
homogenizer using a teflon pestle. The homogenate was spun down at 1000g for 10 
minutes, the supernatant collected, and the pellet resuspended in another 250µl of 
sucrose/HEPES buffer and spun down again. The supernatant was collected and 
combined with the original supernatant on ice. The combined supernatants were spun 
down at 1000g for 6 minutes. The resulting supernatant was collected, and spun down 
at 12,000g for 20 minutes, and the pellet was resuspended in 100µl of Hepes/EDTA 
buffer and spun down at 12,000g for 20 minutes. The supernatant was discarded, and 
the synaptosomal pellet was resuspended in another 75µl of Hepes/EDTA buffer and 
spun down again at 12,000g for 20 minutes.  Protein concentration was determined 
using the BCA assay.  Protein lysates were separated on a 10% SDS gel. Blots were 
probed with anti-rabbit REDD1 (1:1000), (Cell Signaling) primary antibody overnight 
at 4°C. Blots were then incubated with goat anti-rabbit horseradish peroxidase linked 
IgG. Protein bands were visualized by chemiluminescence.  
 
Statistics 
 For all experiments, data was analyzed by a one-way or repeated measures ANOVA.  
If main effect was achieved, pairwise comparisons were performed by the Bonferroni-
Dunn post-hoc test.  A value of p ≤ 0.05 was considered to be statistically significant.  
Statview 4.5 software (SAS Institute Inc., Cary, NC) was used for all statistics.   
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Results 
Constitutive Cav1.2 heterozygous mice display anti-depressive behavior 
To examine the role of Cav1.2 in depressive-like behavior, Cav1.2 heterozygous (HET) 
mice were tested in the forced swim test (FST), a behavioral test previously described 
to measure depressive-like behaviors in mice and in the sucrose preference test, a 
related behavioral paradigm (31) with greater validity as a test for depression (32), that 
measures anhedonia (reflected as decreased sucrose consumption) (33), a core 
component of depression.  In FST, HET mice displayed significantly more time 
mobile compared to wildtype (WT) littermates (Figure 1a; main effect of genotype 
F1,23 = 6.334; p < 0.05), supporting  an anti-depressive phenotype.  In the sucrose 
preference test, HET mice showed significantly higher sucrose preference compared to 
WT mice (Figure 1b; main effect of genotype, F1,8 = 5.719; p < 0.05). 
 
Focal knockout of Cav1.2 in the prefrontal cortex results in anti-depressive 
behavior 
Next to test the role of Cav1.2 channels in the prefrontal cortex (PFC) in 
depressive like behavior, focal knockout of Cav1.2 was generated by injection of 
AAV-Cre into the PFC of cacna1cfl/fl mice. These mice were tested in FST. Mice 
harboring focal KO of Cav1.2 in the PFC spent significantly more time mobile in FST 
compared to AAV-GFP injected control mice (Figure 2a; main effect  
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of viral vector, F1,7 = 4.945; p < 0.05), demonstrating an anti-depressive phenotype.  
To test the specificity of Cav1.2 in mediating the anti-depressive phenotype, we 
generated focal knockdown of Cav1.3, the other neuronal L-type Ca
2+ channel (LTCC) 
isoform in the PFC using AAV-expressing Cav1.3 siRNA.  Knockdown of Cav1.3 had 
no effect on depressive-like behavior in FST. There was no significant difference in 
AAV-Cav1.3 siRNA injected mice compared to AAV-Cav1.3 mismatch control virus 
injected mice (Figure 2b). These results demonstrated that knockout of Cav1.2 in the 
PFC regulates depressive-like behavior. 
 
Focal knockout of Cav1.2 in the ventral or dorsal hippocampus does not 
modulate depressive-like behavior 
To test the role of Cav1.2 in the hippocampus on depressive-like behavior, we 
generated mice with focal knockout of Cav1.2 in the ventral hippocampus (vHPC), a 
brain region implicated in depressive-like behaviors (34), with AAV-Cre. As a control 
region, in a separate cohort of mice, we generated focal knockout of Cav1.2 in the 
dorsal hippocampus (dHPC). Neither the vHPC (Figure 2c) nor the dHPC (Figure 2d) 
Cav1.2 KO mice showed any difference in time spent mobile in FST compared to 
control mice. These findings demonstrate that Cav1.2 in the HPC is not involved in 
regulating depressive-like behavior in mice. 
 
Focal KO of Cav1.2 in glutamatergic neurons of the prefrontal cortex does not 
modulate depressive-like behavior 
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As glutamatergic neurons of the PFC have been shown to regulate depressive-
like behavior (35) and as Cav1.2 are expressed in most excitable glutamatergic neurons 
(36), we used an AAV-Cre driven by a CaMK2 promoter (AAV-CaMK2-Cre) to 
selectively knockout Cav1.2 in the CaMK2-expressing glutamatergic neurons to test 
the role of Cav1.2 in this subset of neurons in the PFC in mediating the anti-depressive 
phenotype observed in Cav1.2 HET mice. Interestingly, mice with focal KO of Cav1.2 
in glutamatergic neurons of the PFC did not show a difference in sucrose preference 
(Figure 3a) or FST (Figure 3b) compared to AAV-GFP control mice.  
 
REDD1 protein levels are lower in the prefrontal cortex of Cav1.2 heterozygous 
mice  
We next explored potential Cav1.2-mediated molecular mechanisms in the PFC 
underlying the anti-depressive-like phenotype observed in Cav1.2 HET mice. We 
measured levels of REDD1 protein, since it was shown to be expressed at lower levels 
in the PFC of depressed humans as well as in the PFC of rats subjected to chronic 
unpredictable stress, a rodent model of depression (26).  Examination of REDD1 
levels in the PFC using Western blot analysis revealed that HET mice have 
significantly lower levels of REDD1 protein in the PFC compared to WT (Figure 4).  
 
REDD1 overexpression in PFC reverses the anti-depressive phenotype in HET 
mice 
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Since REDD1 has been shown to regulate depressive-like behaviors (24), we 
next tested whether REDD1 is responsible for the anti-depressive phenotype observed 
in Cav1.2 HET mice.  REDD1 was over-expressed  in the PFC of HETs by  bilateral 
stereotaxic delivery of a REDD1-expressing viral vector (AAV-REDD1) (26). AAV-
REDD1 injected HET mice showed significantly lower sucrose preference compared 
to HET mice injected with control AAV-eYFP  (Figure 5; main effect of viral vector, 
F1, 17 = 7.191; p < 0.05), indicating that over-expression of REDD1 completely 
reversed the anti-depressive phenotype observed in the HETs (Figure 5). These results 
demonstrate that REDD1 in the PFC is responsible for the anti-depressive phenotype 
observed in Cav1.2 HET mice. 
 
Discussion 
   
In this study, we report that Cav1.2 plays an important role in regulating 
depression-related behaviors.  We find that constitutive Cav1.2 HET mice exhibit an 
anti-depressive phenotype using FST and the sucrose preference test.  Our findings are 
consistent with previous findings of Dao et al. (2010) (4) where they report that 
constitutive Cav1.2 HET mice exhibit an anti-depressive phenotype using FST and the 
tail suspension model of depression.  We extend this finding and demonstrate for the 
first time that Cav1.2 channels in the PFC and not the ventral or dorsal hippocampus is 
responsible for the anti-depressive phenotype. We further demonstrate for the first 
time that the depression-related protein, REDD1, is altered in the PFC of Cav1.2 HET 
mice and that REDD1 is responsible for the anti-depressive behavior seen in this  
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mouse model.   Taken together, this study directly links a role of Cav1.2 in the PFC in 
regulating depressive-like behavior. 
 
CACNA1C SNPs and depression 
Numerous studies have associated genetic variants in CACNA1C with 
depression (3, 5, 21, 37).   All reported SNPs to date are present in noncoding intronic 
or untranslated 5’ and 3’ regions and recent studies have explored the consequence of 
these noncoding SNPs on transcriptional regulation of CACNA1C.  Two studies have 
found that one of the most common and widely reproduced intronic SNPs rs1006737 
in major depressive disorder and also in bipolar disorder and schizophrenia, results in 
higher CACNA1C mRNA levels in human iPSC-derived neurons from carriers of the 
homozygous SNP (24, 38) and in human brain (24).    This data suggests that higher 
levels of cacna1c (Cav1.2) results in depression.  This is consistent with our findings 
in Cav1.2 HET mice that have lower cacna1c mRNA levels resulting in an anti-
depressive phenotype.  Interestingly, one of the most commonly associated CACNA1C 
SNP, rs 1006737, is an intronic SNP. Although several studies have tried to reveal the 
functional consequence of one of the most commonly associated CACNA1C SNP, rs 
1006736 and have had varied results, it is clear that there exists a functional 
consequence (5, 24, 38, 39).  
 
PFC circuitry, cell types and depression-related behavior 
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Dao et al., (4) reported that a functional consequence of global Cav1.2 
heterozygous knockout was a depressive-like phenotype in mice. However, the 
relevant brain region, cell type and potential molecular mechanisms downstream of 
Cav1.2, had yet to be identified. Our finding that Cav1.2 plays a role in the PFC in 
regulating depression-related behavior is consistent with a growing body of evidence 
that dysfunction of the PFC underlies depression (11, 15, 35).  Human imaging and 
postmortem studies demonstrate structural and functional changes in the PFC of 
patients suffering from major depressive disorder (6, 7).  Our findings further suggest 
that the antidepressive effect seen in Cav1.2 HET mice is a result of loss of Cav1.2 in 
non-glutamatergic neurons of the PFC as knockout of Cav1.2 in glutamatergic neurons 
using focal delivery of AAV-CamK2-Cre into the PFC has no effect on depressive-
like behavior.  Non-glutamatergic neurons that are immuno-reactive for calcium 
binding proteins in the PFC have been shown to be altered in major depression (40). 
These GABAergic interneurons exert inhibitory control over pyramidal projection 
neurons of the PFC (41). Although the expression of Cav1.2 in PFC GABAergic 
neurons has not been examined, Cav1.2 is highly expressed in cultured GABAergic 
neurons of the cerebral cortex (42) and in the hippocampus (43). LTCCs have been 
found to regulate parvalbumin expression and interneuron development (44), 
suggesting that there could be lower levels of parvalbumin expression in Cav1.2 HET 
mice. Taken together, we propose that PFC Cav1.2 KO results in decreased 
parvalbumin interneuron activity, leading to decreased inhibition of glutamatergic 
neurons, resulting in an overall increase in PFC output.   This hypothesis is consistent 
with the observation that decreased function of NMDA receptors in the PFC that 
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closely interact with LTCCs has been shown to predominantly decrease the activity of 
PFC interneurons (45). Moreover, in line with our hypothesis, Covington et al., (11) 
suggest that a net increase in the output of PFC projections neurons likely underlies 
the modulation of depressive-like behavior via optogenetic stimulation of the PFC.  
Future studies knocking out Cav1.2 in GABAergic interneurons of the PFC will serve 
to further address these questions. 
 
REDD1 and depressive-like behavior 
Another novel finding from this study is that we identified REDD1 as a 
molecular target downstream of Cav1.2 that is responsible for the anti-depressive 
phenotype in cacna1c HET mice. Cacna1c HETs show lower REDD1 protein in the 
PFC and REDD1 over-expression was sufficient to reverse the sucrose preference 
phenotype. Consistent with lower REDD1 protein resulting in an anti-depressive 
phenotype, higher REDD1 has been reported in human depressed patients as well as in 
rodent models of depression (26).  
Activation of REDD1 promotes protein phosphatase 2A-dependent de-
phosphorylation of molecules that have been linked to depressive- and anxiety-like 
behaviors. One interesting molecular target downstream of REDD1 is the Forkhead 
Box, Class O transcription factors (FoxO). FoxOs have been shown to regulate 
emotional behavior (46). Specifically, FoxO1 is associated with anxiety behaviors, 
whereas FoxO3a is associated with anti-depressive behaviors (46). FoxOs are directly  
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regulated by REDD1 as well as by downstream targets of REDD1, such as Akt (Figure 
6), (47, 48). REDD1 promotes PP2A dependent de-phosphorylation of Akt (49), 
which leads to reduced phosphorylation and therefore activation of FoxO1 and 
FoxO3a (50). Therefore, we hypothesize that the Cav1.2 HETs, which have 
significantly lower REDD1 in the PFC, have higher phosphorylation and activity of 
Akt, leading to increased phosphorylation, hence inhibition of FoxO1 and FoxO3a, 
resulting in an anti-depressive phenotype.  Future molecular studies are needed to 
confirm this hypothesis. 
 In summary, in this report we identify the PFC as a key brain region where 
Cav1.2 and its molecular pathways exert their effects on regulation of depressive-like 
behavior. The above findings advance our understanding of Cav1.2 in depression by 
showing that decreased Cav1.2 in the non-glutamatergic neurons of the PFC regulates 
depressive-like behaviors.  
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Chapter 4: Cacna1c mediates survival of adult newborn hippocampal neural 
precursor cells. 
 
Intoduction 
CACNA1C was recently identified in the largest human genome-wide study to 
date as one of only two genes, and one of only four gene loci, presenting a common 
risk factor across five major forms of neuropsychiatric illness: autism, bipolar 
disorder, major depression, schizophrenia, and attention deficit hyperactivity disorder 
(ADHD) (1). Currently, it is not known how voltage gated calcium channel activity 
genes have such pleiotropic effects on psychopathology. CACNA1C encodes the 
voltage-gated L-type calcium channel (LTTC) Cav1.2, which is activated upon 
transient changes in membrane potential to allow influx of calcium into the cell, which 
activates downstream pathways resulting in transcription of genes such as that 
encoding for brain derived neurotrophic factor (BDNF) (2, 3).  Cav1.2 has been shown 
to play an important role in synaptic plasticity and a number of behaviors and 
phenotypes related to neuropsychiatric illness, including drug addiction (4-6), reward-
driven behavior (7, 8), establishment and extinction of fear conditioning (9, 10), and 
normal cognition (11, 12). We and others have also shown that Cav1.2, and not the 
other brain-specific LTCC subunit Cav1.3, mediates anxiety-like behavior in mice (13, 
14). Specifically, forebrain-cacna1c cKO mice show higher anxiety-like behavior in 
the open field test, light dark conflict test, and the elevated plus maze test (13), and 
anxiety is a prominent component of all of the neuropsychiatric illnesses in which 
CACNA1C has thus far been implicated.  
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Regulation of adult hippocampal neurogenesis (HPC NG), in which newborn 
neurons are continually incorporated into the dentate gyrus of the hippocampus 
(HPC), has been implicated in the pathophysiology of various neuropsychiatric 
disorders including depression and schizophrenia (15-19). The neurogenesis theory of 
depression hypothesizes that since stress is a core component of depression, and stress 
modulates adult HPC NG and there is hippocampal atrophy in depressed patients, 
adult HPC NG may underlie the pathophysiology of major depression (18). 
Furthermore, numerous animal studies show that antidepressant treatment, in 
particular, monoaminergic antidepressants like imipramine and fluoxetine require 
adult HPC NG to exert its antidepressant effects (20-22), further supporting the 
involvement of adult HPC NG in affective disorders. Although such studies have not 
been performed in humans, postmortem studies in depressed patients reveal decreased 
dentate gyrus size and granule cell number, suggesting decreased adult HPC NG (22). 
Ericksson et al. (23) provided the first direct evidence for adult HPC NG in humans. 
More recently, Spalding et al., confirmed these findings and further showed that about 
one third of HPC neurons are subject to change and that the extent of adult NG is 
comparable in adult humans and adult mice (24).   
Previously, Deisseroth et al. have shown that LTCCs exert bi-directional 
regulation of proliferation of adult-derived neural precursor cells (25). However, these 
experiments did not look in vivo to determine whether the two forms of LTCCs, 
Cav1.2 and Cav1.3, exert different or complementary roles, which could serve to guide 
future therapeutic approaches in patients.  Here, we apply genetic approaches to 
address this important issue, using both the Cre-loxP system and virus-mediated gene 
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transfer in mice, to achieve in vivo spatial and temporal control of Cav1.2 and Cav1.3 
gene expression. 
 
Methods and Materials 
Animals 
All experimental procedures were conducted in accordance with the rules of the Weill 
Cornell Medical College and University of Iowa Carver College of Medicine 
Institutional Animal Care and Use Committees. All animals were housed in 
temperature controlled conditions, provided food and water ad libitum, and maintained 
on a 12-hr light/dark cycle (7 A.M. to 7 P.M.).  Forebrain-cacna1c cKO mice, and 
cacna1c fl/fl mice were generated as previously described (13, 26).  
 
Surgeries 
Stereotaxic surgery was performed in 8 week old mice as described (13, 26). Briefly, 
anesthesia was induced by intraperitoneal (i.p.) injection of ketamine (1000mg/kg) 
xylazine cocktail (200mg/kg). A midline incision was made, local anesthesia 
(Marcaine) applied, the head leveled and holes formed through the skull using a 25 
gauge needle. Region-specific deletion of cacna1c was generated by manual bilateral 
infusion of AAV-Cre (Vector BioLabs, Philadelphia, PA), (0.75ul/side) into the 
hippocampus of cacna1cfl/fl mice through a 2.5ul Hamilton syringe at a rate of 
0.1ul/minute. AAV-GFP (Vector BioLabs, Philadelphia, PA) was used as a control. 
Region-specific knockdown of cacna1d was generated by manual bilateral infusion of 
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0.5ul per side of AAV-cacna1d siRNA (4) into the hippocampus through a 2.5ul 
Hamilton syringe at a rate of 0.1ul/minute. AAV-mismatch siRNA was used as a 
control virus. The coordinates for the HPC were anterior-posterior -2mm; medial-
lateral ±1.6mm; dorsal-ventral -1.8mm, at a 10˚ angle.  The needle was left in place 
for an additional 5 min after infusion in order to ensure complete delivery of virus. 
After a minimum of 3 weeks to allow for maximal virus expression, mice were 
administered 50mg/kg BrdU for 5 days and transcardially perfused with 4% 
paraformaldehyde (PFA) 24hrs after the last injection of BrdU.  
 
P7C3-A20 treatments 
All mice were single housed for the duration of their treatment. Forebrain-cacana1c 
cKO and wild type (WT) littermate mice received 10mg/kg P7C3-A20 or vehicle (5% 
DMSO, 20% cremaphor in 5% dextrose), i.p, twice a day 28 days, or twice a day for 7 
days, starting after P60. Mice were transcardially perfused with 4% PFA 24hrs after 
the last BrdU injection. In separate experiments, brains were flash frozen and 
processed for BDNF ELISA. 
 
BDNF ELISA  
Mature BDNF protein level was measured using the BDNF Emax ImmunoAssay 
(ELISA) system (Promega, Madison, WI), with recombinant mature BDNF as a 
standard. Standard and samples were performed in duplicate, with each group 
containing 10 to 14 samples. Protein was extracted and quantified following the 
manufacturer protocol. Tissue samples were homogenized in lysis buffer (150mM 
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NaCl, 1% Triton X-100, 25mM HEPES, 2mM NaF) containing phosphatase and 
protease inhibitors, and then incubated by rotation at 4C for 1 hour. Homogenized 
tissue was centrifuged at maximum speed and the supernatant containing total protein 
was collected and quantified using the BCA protein assay kit (Thermo Fisher 
Scientific, Rockford, IL). Each sample was diluted 1:1 with block and sample buffer 
(BSB), and placed in designated wells of a 96-well plate previously coated with 
BDNF antibody in carbonate buffer (25mM Na2CO3 and 25mM Na2HCO3, pH 9.7, 
incubated at 4C), followed by blocking with BSB. A second coating of primary anti-
human BDNF antibody was added, followed by horseradish peroxidase-conjugated 
secondary antibody. The colorimetric reaction was initiated by tetramethylbenzidine. 
After 10 minutes, the reaction was stopped by addition of 1N HCl, and absorbance 
was read at 450 nm on a plate reader (iMark Absorbance Microplate Reader, Bio-Rad 
Laboratories, Hercules, CA). 
 
Fluorescent Immunohistochemistry 
Cav1.2 fluorescent immunohistochemistry was performed to confirm elimination of 
Cav1.2 as previously described (13, 26). Fluorescent immunohistochemistry was also 
used to confirm injection placement. Mice were transcardially perfused with 4% PFA, 
and brains were dissected and post-fixed overnight in 4% PFA followed by cryo- 
protection in 30% sucrose at 4C for at least 72 hours. Forty um-thick sections 
spanning the hippocampus were obtained using a sliding microtome and incubated in 
anti-chicken GFP (1:5,000) (Aves Labs, Tigard, Oregon) and anti-rabbit glial fibrillary 
acidic protein (GFAP) (1:1000) (Invitrogen) primary antibody overnight at 4C. 
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Sections were rinsed in 0.1M phosphate-buffer (PB) and incubated with Alexa Fluor 
488 (1:300) and Alexa Fluor 568 (1:300) antibody for 1 hour at room temperature.   
 
BrdU Staining 
As previously described (27-30), 24 hours after the final BrdU administration mice 
were sacrificed by transcardial perfusion with 4% paraformaldehyde at pH 7.4, and 
their brains were processed for immunohistochemical detection of incorporated BrdU 
in the hippocampus. Dissected brains were immersed in 4% paraformaldehyde 
overnight at 4 °C, then cryoprotected in sucrose before being sectioned into 40 μm 
thick free-floating sections. Unmasking of BrdU antigen was achieved through 
incubating tissue sections for 2 hours in 50% formamide / 2X saline-sodium citrate 
(SSC) at 65 °C, followed by a 5 minute wash in 2X SSC and subsequent incubation 
for 30 minutes in 2M HCl at 37 °C. Sections were processed for immunohistochemical 
staining with mouse monoclonal anti- BrdU (1:100). The number of BrdU+ cells in 
the entire dentate gyrus subgranular zone (SGZ) was quantified by counting BrdU+ 
cells within the SGZ and dentate gyrus in every fifth section throughout the entire 
hippocampus and then normalizing for dentate gyrus volume using Nikon Metamorph 
software. 
 
Corticosterone levels 
To measure baseline and stress-induced corticosterone levels, plasma samples were 
isolated from 7-15 week old forebrain-Cav1.2 cKO and WT mice at 1:00-2:00pm and 
stored at -20°C. For all restraint stress experiments, mice were restrained for 30min in 
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decapicones (Snyder et al., 2011). Plasma corticosterone levels were measured using 
the high sensitivity corticosterone enzyme immunoassay (EIA) kit (AC-15F1, 
Immunodiagnostic Systems, Fountain Hills, AZ). Samples were analyzed in duplicate. 
Concentrations were determined as per manufacturer’s instructions.  
Morphometric Analysis of Hippocampal Size 
As previously described (31), PFA-fixed mouse brains were sectioned in the coronal 
plane, paraffin-embedded, sectioned at 8 uM thickness, and stained with hematoxylin 
and eosin. Histological sections were obtained at 50-mm intervals. Measurements of 
the hippocampus, dentate granular cell layer, and forebrain were taken at the coronal 
level in which CA1 approaches the midline and the upper blade of the dentate gyrus 
runs parallel to the surface of the brain. An ocular lens fitted with an etched grid was 
used to measure the dentate, CA1 and CA3 height and neuronal size (60X), as well as 
hippocampal dimensions (2X).  
 
Results 
Cav1.2 but not Cav1.3 L-type calcium channels are necessary for adult 
hippocampal neurogenesis.  
We first examined adult hippocampal neurogenesis (HPC NG) in forebrain- 
cacna1c cKO mice (Figure 1a). All mice received intraperitoneal (i.p.) injections of 
the cell proliferation tracer, bromodeoxyuridine (BrdU), once a day, for a total of 5 
days. Mice were transcardially perfused with 4% paraformaldehyde (PFA) 24hrs after 
the last injection of BrdU. Forty micron brain sections were immunostained for BrdU, 
and the number of immunoreactive cells was counted in the subgranular and granular  
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cell layers of the dentate gyrus. Forebrain-Cav1.2 cKO mice show significantly lower 
(approximately 50% lower) number of BrdU positive cells compared to wildtype 
littermate controls (Figure 1b).  
Next, to directly test the effect of Cav1.2 knockout in the HPC on adult HPC 
NG, we generated focal knockout of Cav1.2 via stereotaxic delivery of AAV-Cre-GFP 
into the HPC of adult cacna1cfl/fl mice (Figure 2a, b).   Cav1.2 KO in the HPC resulted 
in significantly lower number of BrdU positive cells compared to that seen in control 
AAV-GFP injected mice (Figure 2c), similar to that observed in forebrain-Cav1.2 cKO 
mice (Figure 1b).  
The other neuronal LTCC, Cav1.3, has also been shown to be involved in 
affective behaviors (9, 32), which have been associated with changes in adult HPC NG 
(22). Specifically, Cav1.3 KO show anti-depressive-like phenotype as measured by 
decreased immobility in forced swim test and tail suspension test, an anxiety 
phenotype as measured by increased time in open arms of the EPM (32) as well as a 
deficit in the consolidation of fear conditioning (9). Therefore we generated focal 
knockdown of Cav1.3 in the HPC of adult C57BL/6 mice via stereotaxic delivery of 
AAV-Cav1.3 siRNA (Figure 2d, e).  Knockdown of Cav1.3 did not affect the number 
of BrdU immunoreactive cells compared to control scrambled siRNA injected mice 
(Figure 2f). These results demonstrate that HPC Cav1.2, and not Cav1.3 regulates adult 
HPC NG. 
 
Cav1.2 channels are necessary for survival and not proliferation of adult born 
neural progenitor cells.  
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Adult HPC NG consists of several different stages which can be loosely 
grouped as proliferation and survival (33). Various factors that affect adult HPC NG 
such as neurotrophic factors, antidepressant drugs and stress, have different effects on 
the proliferation and survival in the adult dentate gyrus (34, 35). Therefore, we 
investigated whether Cav1.2 regulates the proliferation or survival stage of adult HPC 
NG. To examine proliferation of adult born neural progenitor cells (NPC), 8-week old 
male forebrain-cacna1c cKO received 1 injection of BrdU. Mice were perfused 1hr 
after the BrdU injection, and brains were sectioned and processed for 
immunohistochemical staining for BrdU.  To examine survival of adult NPCs, brains 
were processed 30 days after a single injection of BrdU. One hour after BrdU 
injection, there was no difference in number of BrdU positive cells in forebrain-
cacna1c cKO compared to WT (Figure 3a). However, 30days after a single injection 
of BrdU, there were significantly lower number of BrdU positive neurons in 
forebrain-cacna1c2 cKO versus WT (Figure 3b). These results demonstrate that 
forebrain-cacna1c cKO have normal proliferation but have a significant deficit in the 
survival of newborn neurons in the dentate gyrus. 
 
Lower adult HPC NG in forebrain-cacna1c cKO does not affect hippocampus size  
Deficits in adult HPC NG can result in changes in the size of the HPC, such as 
those observed for other mouse models with more severe deficit in adult HPC NG 
(30). Moreover, neurotrophic factors and exercise, which increase adult HPG NG, 
increases the size of the HPC, suggesting that changes in HPC size may correlate with 
HPC NG and have functional consequences (36). Furthermore, decrease in HPC size 
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in depressed patients is one of the core components of the neurogenesis hypothesis of 
depression; it is assumed that since depressed patients have smaller HPC, they also 
have a deficit in HPC NG (18).  Therefore, we compared size of the hippocampus and 
its subregions between forebrain-cacna1c cKO and their WT littermates. Forebrain-
cacna1c cKO mice displayed normal hippocampus size (Figure 4a) as well as normal 
dentate gyrus, CA1 and CA3 thickness (Figure 4b). Therefore, impaired adult HPC 
NG in the forebrain-cacna1c cKO does not affect hippocampal morphology.  
 
Lower adult HPC NG in forebrain-cacna1c cKO is not mediated by 
gluococorticoids.  
We have previously reported that forebrain-Cav1.2 cKO display an anxiety-
like phenotype (13). Corticosterone, the primary glucocorticoid produced by the 
adrenal cortex, has been shown to induce anxiety-like behaviors (37) via the 
glucocorticoid receptors (38).  Corticosterone (37) and glucocorticoid receptors have 
also been shown to modulate the connectivity and integration of newborn neurons in 
the adult hippocampus (39, 40). Therefore, we considered corticosterone as a potential 
mechanism underlying the impaired survival of newborn neurons observed in 
forebrain-cacna1c cKO mice. Corticosterone levels were measured in the trunk blood 
of forebrain-cacna1c cKO and WT mice at basal conditions and following acute 
immobilization stress. There was no difference in corticosterone levels in either basal 
condition or after acute immobilization stress (Figure 5), suggesting that the deficit in 
adult HPC NG in forebrain-cacna1c cKO is not mediated by corticosterone.  
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The neuro-protective aminopropyl carbazole P7C3A-20 rescues adult HPC NG 
deficit in forebrain-cacna1c cKO. 
The compound P7C3-A20 has been identified as a pro-neurogenic agent that 
specifically improves survival of new born neurons (30). Thus, we next examined if 
P7C3-A20 treatment can rescue the deficit in survival of newborn neurons in 
forebrain-cacna1c cKO mice. We examined levels of doublecortin (DCX), a 
molecular marker of new born neurons committed to neuronal fate, unlike BrdU, 
which is unable to distinguish between neuronal versus non-neuronal committed cells 
(17). P7C3-A20 treatment increased the number of newborn neurons in forebrain-
cacna1c cKO and WT mice (Figure 6a), and significantly increased DCX mRNA in 
the HPC of both forebrain-cacna1c cKO and WT (Figure 6b), thereby rescuing the 
Cav1.2 induced deficit in adult HPC NG.    
We additionally tested the effect of the selective serotine reuptake inhibitor 
(SSRI) fluoxetine, and found that fluoxetine treatment also increased DCX labeling in 
forebrain-cacna1c cKO and WT (Figure 7a). However, fluoxetine treatment did not 
affect DCX mRNA levels in forebrain-cacna1c cKO and WT (Figure 7b). 
 
P7C3-A20 rescues adult HPC NG deficit in forebrain-cacna1c cKO via a BDNF 
independent mechanism.  
A downstream target of Cav1.2, brain derived neurotrophic factor (BDNF), is 
known to regulate adult HPC NG (41, 42). Additionally SSRIs such as fluoxetine 
work in part via increasing BDNF (42).   Thus we next examined levels of BDNF 
protein using ELISA.  We found that forebrain-cacna1c cKO have significantly lower 
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levels of BDNF protein compared to WT mice (Figure 8a), suggesting BDNF as a 
potential mechanism that underlies the neurogenesis deficit in forebrain-cacna1c cKO 
mice.   Next we examined the effect of P7C3-A20 and fluoxetine on BDNF levels in 
forebrain-cacna1c cKO and WT mice.  We found that P7C3-A20 had no effect on 
hippocampal BDNF in either genotype (Figure 8a).  In contrast, fluoxetine treated 
mice showed the expected robust increase in hippocampal BDNF in WT mice and also 
in forebrain-cacna1c cKO mice (Figure 8b). These results suggest P7C3-A20 rescues 
the deficit in adult HPC NG in the forebrain-cacna1c cKO via a BDNF independent 
mechanism. 
 
Discussion 
Although LTCCs have been implicated to be involved in adult HPC NG (43), 
the specific isoform of LTCC that modulates adult HPC NG had not yet been 
identified. Here, we report for the first time, that Cav1.2, and not Cav1.3, regulates 
adult HPC NG. We further show in forebrain-cacna1c cKO that Cav1.2 specifically 
regulates the survival and not the proliferation of adult born newborn precursor cells. 
The Cav1.2-regulated deficit in adult HPC NG is likely not a developmental 
compensatory effect as focal knockout of Cav1.2 specifically in the adult dentate gyrus 
of the HPC also results in a severe deficit in adult HPC NG.  
We also show that P7C3-A20 restored adult HPC NG as measured by DCX 
protein and mRNA (Figure 6), without correcting BDNF levels in forebrain-cacna1c 
cKO (Figure 8a). Fluoxetine on the other hand, increased DCX protein, but not DCX  
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mRNA (Figure 7) and drastically increased BDNF in both WT and KO mice (Figure 
8b).    
Interestingly, the BDNF Val66Met human knockin mouse model has been 
shown to be resistant to the neurogenic effects of fluoxetine (42). Since P7C3-A20 
rescues adult HPC NG in a BDNF independent mechanism, this compound could be a 
better treatment for individuals with BDNF genetic variants. We find that fluoxetine 
and P7C3-A20 alter adult HPC NG as measured by DCX via different molecular 
mechanisms (i.e. via BDNF dependent and independent mechanism), but the two 
treatments also affect different aspects (translation versus transcription) of DCX 
expression.  Recent studies have highlighted the mTOR pathway at that controls 
protein translation at neuronal synapses, in the antidepressant actions of ketamine (44). 
It remains to be explored if fluoxetine regulates the mTOR pathway.   However it is 
possible that even though fluoxetine requires two weeks to exert its behavioral anti-
depressive effects, it could recruit a protein translation mechanism at the synapse. 
Collectively, these results show that Cav1.2-induced deficit in adult HPC NG can be 
rescued via both BDNF dependent and independent mechanisms.  
The role of adult HPC NG in mood behaviors has been a topic of controversy 
(22). Future experiments will test whether the deficit in adult HPC NG observed in the 
forebrain-cacna1c cKO, which have an anxiety-like phenotype (13), is involved in 
modulating mood. If adult HPC NG is found to be involved in mood regulation in the 
forebrain-cacna1c cKO, since CACNA1C has been selectively implicated in 
neuropsychiatric disease, pharmacologic restoration of HPC NG, such as through 
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treatment with the P7C3-class of neuroprotective agents, may provide a new 
opportunity for therapeutic intervention in patients.   
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Chapter 5: Loss of Cav1.2 in the hippocampus results in long-term molecular 
changes in the nucleus accumbens that underlies sustained cocaine context-
association memory. 
 
Introduction 
Drug addiction is a chronic, relapsing disorder (1-3). Relapse can be triggered 
by the drug itself, or by a drug-associated cue such as drug related context, despite 
extended drug-free periods (4-6). Preventing relapse is one of the major goals as well 
as a major challenge of treating cocaine addiction. It is widely accepted that cocaine-
induced changes in gene expression and synaptic plasticity via activation of molecular 
signaling pathways within the brain’s reward circuitry underlies the high rates of 
relapse despite prolonged abstinence from cocaine (7, 8).  
L-type calcium channels (LTCCs) mediate activity-dependent gene expression 
and synaptic plasticity that underlies long-term memory mechanisms (9-12). We and 
others have shown that the two main LTCC isoforms expressed in the brain, Cav1.2 
and Cav1.3, are necessary for long-term cocaine-induced molecular and behavioral 
plasticity (13-15) and cocaine seeking behavior (16-18). Interestingly, two studies 
have reported that Cav1.2 may also contribute to loss of memory (19, 20), suggesting 
that LTCCs can activate pathways that contribute to formation and loss of memories. 
The hippocampus (HPC) is a brain region that is critically involved in 
regulating context-reward memories (21-24). Indeed, it is essential for acquisition of 
cocaine conditioned place preference (CPP), a cocaine reward-context association task 
(25). Cocaine CPP is a simple, non-invasive procedure wherein animals are trained to 
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associate a specific context with the rewarding effects of a drug. When animals are 
allowed to freely explore the drug paired and non-drug paired context, they prefer the 
drug-paired context, indicating development of cocaine preference or CPP. LTCCs in 
the HPC are involved in long lasting synaptic changes that are critical for long-term 
potentiation (LTP), a process thought to underlie memory storage (26-29). 
Importantly, the HPC sends glutamatergic projections to the NAc (30, 31), one of the 
most important brain regions involved in reward in general (32) and more specifically, 
in cocaine reward (33, 34). The HPC-NAc pathway is necessary for expression of 
cocaine CPP behavior (33-35). 
Ca2+ signaling pathways play a key role in activating mechanisms necessary 
for long-term memory formation.  The balance between kinase versus phosphatase 
activity has been proposed to underlie LTP, for memory storage, or LTD, for memory 
loss, respectively (36). The calcium influx from Cav1.2 channels activates 
Ca2+/calmodulin (CaM), which can then activate either a kinase or phosphatase 
pathway (37) CaMKII is an essential kinase for synaptic plasticity and memory 
formation (38-41). Activation of CaMKII phosphorylates the GluA1 subunit of the 
AMPA receptor (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors) 
at Ser831, which results in the translocation of GluA2-lacking AMPAR to the surface 
membrane, resulting in increased AMPAR signaling (42).  Increased insertion of 
GluA2 lacking, Ca2+ permeable AMPAR has been shown to mediate cocaine craving 
after long-term abstinence from cocaine (43). Calcineurin, or PP2B, is a Ca2+/CaM-
dependent serine phosphatase that can also be activated by Cav1.2, which decreases 
Ser 831 GluA1 phosphorylation and contributes to memory loss (44).  PP2B can also 
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regulate gene transcription by dephosphorylating its molecular targets such as the 
transcription factor, NFATc3 (nuclear factor of activated T-cells c3) (45-47). Upon 
dephosphorylation, NFATc3 translocates into the nucleus where it associates with 
other proteins to activate gene expression (45-49). 
Together, the above findings suggest that the balance between the CaMKII 
pathway versus the PP2B pathway may dictate long-lasting cocaine-associated 
memories. Therefore, in this study, we examined the effect of knocking out Cav1.2 in 
the HPC on long-lasting expression of cocaine CPP behavior and on molecular 
changes in the HPC, NAc and the prefrontal cortex (PFC), important brain reward 
regions that the HPC projects to.  We find that loss of Cav1.2 in the HPC results in 
persistence of cocaine CPP when examined following 30 days of withdrawal 
compared to control WT mice.   
 
Methods and Materials 
Animals 
All experimental procedures were conducted in accordance with the rules of the Weill 
Cornell Medical College and University Animal Care and Use Committees. All 
animals were housed in temperature controlled conditions, provided food and water ad 
libitum, and maintained on a 12-hr light/dark cycle (7 A.M. to 7 P.M.).  Homozygous 
cacna1cfloxed/floxed (cacna1cfl/fl) male mice were generated as previously described (Lee 
et al., 2012).  
 
Surgeries 
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Stereotaxic surgery was performed in 8 week old mice as described (Lee et al., 2012). 
Briefly, anesthesia was induced by intraperitoneal (i.p.) injection of ketamine 
(1000mg/kg) xylazine cocktail (200mg/kg). A midline incision was made, local 
anesthesia (Marcaine) applied, the head leveled and holes formed through the skull 
using a 25 gauge needle. Region-specific deletion of Cav1.2 was generated by manual 
bilateral infusion of AAV-Cre (Vector BioLabs, Philadelphia, PA), (0.5ul/side) into 
the hippocampus of cacna1cfl/fl mice through a 2.5ul Hamilton syringe at a rate of 
0.1ul/minute. AAV-GFP (Vector BioLabs, Philadelphia, PA) was used as a control. 
The coordinates for the hippocampus were -1.4 AP, +1.2 ML, -2 DV, at a 10˚ angle. 
The mice were allowed to recover for at least 2 weeks to ensure maximal knockout of 
Cav1.2.    
 
Behavior 
Cocaine induced conditioned place preference (CPP) was performed as previously 
described (35) (Figure 1). Briefly, mice were placed into a three chamber place 
preference apparatus (Med Associates Inc, St Albans, VT, USA) with two 
experimental chambers that have distinct floors, lighting and wall color and one center 
habituation chamber. The three chambers were separated by a guillotine door. On Day 
1, mice were placed into the center habituation chamber to acclimate for 1 minute after 
which the guillotine doors on either side of the habituation chamber were opened. The 
mouse then had free access to all three chambers for 20 minutes, during which time  
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spent in each chamber is digitally recorded. If the mice showed preference for one 
experimental chamber on this baseline test, then the preferred chamber was paired 
with saline, and the other experimental chamber was paired with cocaine. On Days 2-
4, mice receive an intra-peritoneal (i.p.) injection of 10mg/kg cocaine immediately 
before being confined to the cocaine paired experimental chamber for 20 minutes. At 
least four hours later, mice received an i.p. injection of saline immediately before 
being confined to the saline paired experimental chamber for 20 minutes. On Day 5, 
the mice were again provided free access to all three chambers for 20 minutes to 
access the acquisition of cocaine CPP. Preference was defined as the difference in 
time spent in the cocaine-paired side on the acquisition test day and baseline test day 
and is reported as a difference score. On Withdrawal Days 1-3 (WD1-3), mice were 
kept in their home cage. On WD4, mice were subjected to another 20 minute CPP test. 
On WD 5-29, mice were kept in their home cage. On WD30, mice were subjected to a 
final 20 minute CPP test. 
 
Western immunoblotting 
Mice were sacrificed by rapid decapitation immediately after the final CPP test on 
WD30. Brains were dissected and the hippocampi sectioned on a 1mm brain block. 
GFP goggles (BLS-Ltd.com) were used to visualize GFP signaling in the HPC and to 
dissect out GFP positive tissue for western immunoblotting. Immunoblotting was 
performed as previously described by Giordano et al., (2010) (17). Twenty µg of 
protein was loaded on 10% SDS-polyacrylamide gels and run at 200V constant 
voltage. Blots were probed with anti-rabbit CaMKII, Thr 286 P-CaMKII, PP2B, Ser 
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197 P-PP2B, NFATc3, Ser240 P-NFATc3, GluA1, Ser 831 P-GluA1, Ser 845 P-
GluA1, tubulin or vinculin antibodies overnight at 4°C. Blots were then incubated 
with goat anti-rabbit horseradish peroxidase-linked IgG. Protein bands were visualized 
by chemiluminescence.   Films were scanned and optical density determined using 
Image J software. 
 
Statistics 
For cocaine CPP, difference score data and for western blots, the optical density data 
was analyzed by t-test.   
 
Results 
Knockout of Cav1.2 in the HPC results in persistence of the expression of cocaine 
CPP following long-term withdrawal 
The associations that are established between contextual cues and the drug 
produce a conditioned response: drug seeking in response to drug-paired cues even in 
absence of drug; and this conditioned response is thought to contribute to compulsive 
drug-seeking behavior and relapse (50-53).  We used cocaine CPP to model this 
phenomena in mice. Cocaine induced CPP has been shown to require the hippocampus 
(HPC) (25).   To test the role of HPC Cav1.2 channels in cocaine CPP behavior, AAV-
Cre was delivered into the HPC of cacna1cfl/fl mice to create focal knockout of Cav1.2 
specifically in the HPC. After allowing for AAV-Cre induced maximal knockout (KO) 
of HPC Cav1.2, mice were conditioned and tested for acquisition of cocaine CPP 
(Figure 1).  Control mice were injected with AAV-GFP.   Knockout of Cav1.2 in the 
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HPC had no effect on acquisition of cocaine CPP as there was no significant 
difference in acquisition between AAV-Cre and AAV-GFP injected mice (Figure 2). 
Mice were then subjected to 3 days of forced withdrawal, from cocaine, during which 
time they were kept in their home cage (Figure 1). Mice were tested for the recall of 
cocaine CPP memory on withdrawal day (WD) 4 and WD30. Interestingly, mice with 
HPC Cav1.2 KO showed persistent maintenance of cocaine CPP memory compared to 
control AAV-GFP injected mice, which showed normal decay of cocaine CPP 
memory across time (Figure 2).  At WD4 there was a non-significant difference 
between the AAV-Cre and AAV-GFP injected mice.  By WD30, AAV-Cre injected 
mice exhibited significantly higher cocaine CPP compared to control AAV-GFP 
injected mice (Figure 2). Thus, knockout of Cav1.2 in the HPC results in persistence of 
cocaine CPP following 30 days of withdrawal.   
 
Knockout of Cav1.2 in the HPC results in long-term molecular changes in the 
nucleus accumbens.    
Next, to examine molecular changes that may underlie the persistent cocaine 
CPP observed in HPC Cav1.2 knockout mice, following behavioral testing on WD30, 
the HPC, NAc and PFC were isolated for western blot analysis.  Interestingly at this 
time point, in the HPC (Figure 3a) and PFC (Figure 3b), there was no difference in 
total or phosphorylated levels of CaMKII, GluA1, PP2B or NFATc3.   
In the NAc, there was significantly higher levels of total CaMKII (Figure 3c). 
No difference in phospho-CaMKII was seen (Figure 3c).  Examination of GluA1 
revealed higher levels of S831 P-GluA1 that did not reach significance.  There was no  
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difference in phosphorylation of GluA1 at S845, a protein kinase A target or in total 
GluA1(Figure 3c).  Examination of PP2B revealed no different in total or 
phosphorylated PP2B.  However total and phospho-NFATc3 were significantly higher 
in the NAc of HPC Cav1.2 KO mice compared to control mice.  
 
Discussion 
In this study, we show that (1) knockout of Cav1.2 in the HPC results in 
persistence of cocaine CPP at withdrawal day 30 (WD30) (2) knockout of Cav1.2 in 
the HPC results in molecular changes in the NAc at WD30 and not the HPC or PFC 
and (3) persistence of cocaine CPP at WD30 is associated with increases in CaMKII 
and P-GluA1 Ser 831, a target of CaMKII, in addition to increase in the transcription 
factor NFATc3.     
 Many studies report that the excitatory projections from the ventral, and not the 
dorsal HPC to the NAc is associated with cocaine seeking behavior (30, 31, 54-58). 
Indeed, the dorsal and ventral HPC differ in behavioral regulation (59-61), LTP 
induction (62) and NMDAR subunit expression (63). Similarly, the NAc is also 
subdivided into more discrete anatomical regions. Recent studies report that ventral 
HPC provides the predominant glutamatergic input to specifically the medial NAc 
shell (30, 31). In the current study, due to the technical limitations of crude dissections 
of GFP positive tissue after AAV-Cre expression, it was not possible to distinguish 
between the dorsal and ventral HPC. Furthermore, in order to collect enough tissue for 
immunoblotting studies, it was also not possible to isolate the medial NAc shell, but 
rather the entire NAc was collected for analysis. However, despite the generalization 
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of various sub-regions of the HPC and NAc, we show, for the first time, that Cav1.2 in 
the HPC regulates the balance of kinase versus phosphatase pathway within the NAc 
to modulate long-term cocaine-context association memory.  
Cocaine memories have previously been shown to shift from one brain region 
to another. For example, when the association between cocaine related cues and 
maintenance of drug seeking becomes habitual, it shifts from the NAc to the dorsal 
striatum (3).  We have previously reported that the cocaine CPP memory in early 
withdrawal from cocaine (1d after last cocaine conditioning) lies in the HPC, as 
indicated by significant changes in molecular pathways involved in cocaine context 
association memory (35). In the current study, we found that after prolonged (31days 
after last cocaine conditioning session) withdrawal from cocaine, the cocaine CPP 
memory transfers from the HPC to the NAc. We did not observe any significant 
molecular changes in the HPC (Figure 3a) on WD30 and instead found significant 
changes in the NAc indicative of activation of the CaMKII pathway (Figure 3c). Total 
and P-PP2B levels remained unchanged in the NAc of HPC Cav1.2 KO mice (Figure 
3c) suggesting that the phosphatase pathway was not activated in these mice. 
Significant increases in total and P-NFATc3 S240 lends further support for the kinase 
pathway, rather than the phosphatase pathway being activated in the NAc of HPC 
Cav1.2 KO mice. NFATc3 is phosphorylated in its basal state (64, 65) and is 
dephosphorylated by LTCC activated PP2B at Ser240 (64-67) . The significant 
increase in P-NFATc3 Ser240 in the NAc of HPC Cav1.2 KO suggests decreased 
activity of PP2B (Figure 3c). 
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Within the NAc, we hypothesize that the effects are mainly in the D1R and not 
D2R medium spiny neurons, as these are the cell-types that have been shown to 
receive the potent glutamatergic input from the ventral HPC (31). Furthermore, D1, 
but not D2 antagonists have been shown to attenuate context induced reinstatement 
(68). Also, cocaine activates D1R which leads to the sequential activation of the cyclic 
AMP/PKA pathway, LTCC (69), and finally CaMKII (70); thereby leading to changes 
in gene expression  that are required for drug associated learning and memory (37, 
70). 
Glutamate induced potentiation at single synapses has been shown to induce 
robust increases in both total CamKII and CaMKII anchored to Cav1.2 (71). We 
propose that following long-term withdrawal, HPC Cav1.2 KO increases glutamate 
release at NAc which then preferentially activates the CaMKII pathway instead of the 
PP2B pathway (Figure 4a), (36, 72) to maintain cocaine-context association memories 
across a prolonged withdrawal period  (Figure 2). The increase in glutamate release 
from the HPC may activate Cav1.2 via NMDAR to then activate Ca
2+/CaM, which 
preferentially activates the CaMKII pathway (Figure 4b). In addition to 
phosphorylating GluA1 Ser831, CaMKII may also activate CREB (cAMP response 
element-binding protein) binding to CRE, to induce transcription of genes such as 
NFATc3, which is a potential explanation for the increase in total NFATc3 in the NAc 
(Figure 3c).  
The HPC is known to project to the PFC, and this pathway has been shown to 
influence NAc activity (73). Moreover, the impairments in glutamate signaling in the 
PFC-NAc pathway is thought to underlie relapse vulnerability, especially after  
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withdrawal from cocaine (74, 75). Since the HPC also projects to the PFC, we asked 
whether HPC Cav1.2 may modulate this aspect of relapse vulnerability. Although we 
did not observe any significant molecular changes in the PFC in the CaMKII or PP2B 
pathways, other mechanisms in the PFC may be involved. For example, the PFC 
receives input from the VTA to then send projections to the NAc to modulate drug 
seeking behavior (76). Therefore, it is possible that the HPC induced molecular 
changes may serve to make the NAc more vulnerable to regulation by the PFC.   
The current study reports novel findings for the role of Cav1.2 in the HPC in 
the long-term maintenance of cocaine CPP memory. Drug addiction is a chronic 
disease, and context induced relapse is the biggest and most treatment resistant 
problem in drug addiction (6). Our findings offer further insight and novel molecular 
mechanisms underlying the maintenance of long-term cocaine-context association 
memory to work towards an effective pharmacological treatment for cocaine 
addiction. 
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Chapter 6: Conclusions & Future Directions 
Recent human and preclinical studies converge to suggest CACNA1C (Cav1.2) 
as a regulator of neuropsychiatric diseases. CACNA1C has been associated with a wide 
range of neuropsychiatric disorders including major depression, bipolar, 
schizophrenia, autism, attention deficit hyperactivity disorder (1), drug addiction (2-4), 
and even in cognitive deficits during normal aging (5, 6), highlighting its wide cast 
effect on symptoms that range from anhedonia to memory impairments.  Although its 
involvement in all these disorders and symptoms has been described, in many 
instances, the specific relevant brain regions and cell types have not yet been 
identified. In this dissertation, I explored the role of cacna1c (Cav1.2) in discrete brain 
regions and cell types (Figure 1) in key processes that underlie neuropsychiatric 
disorders such as anxiety, depression, reward systems and memory.  
In chapter one, I describe the role of Cav1.2 in anxiety-like behavior. I first 
reported that global constitutive cacna1c HET (HET) (Figure 2) mice display anxiety-
like behavior. Forebrain specific Cav1.2 conditional knockout mice (forebrain-
cacna1c cKO) (Figure 2) also display anxiety-like behavior, confirming the regulation 
of this phenotype by neuronal Cav1.2. With regards to the brain region involved, I 
showed a role for Cav1.2 in the prefrontal cortex (PFC), and not the hippocampus 
(HPC), (Figure 2) that modulates anxiety-like behavior. Furthermore, Cav1.3, the other 
neuronal L-type calcium channel (LTCC) isoform, in the PFC, is not involved in 
anxiety-like behaviors. Within the PFC, focal knockout of Cav1.2 in the excitatory 
glutamatergic neurons was sufficient to produce an anxiety-like phenotype.  
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These findings lead to other interesting experimental questions to be answered. 
For example, I have established that Cav1.2 in the excitatory neurons regulate anxiety-
like behavior by showing that AAV-CaMKII-Cre mediated knockout of Cav1.2 in the 
PFC recapitulates the anxiety-like phenotype. The PFC has excitatory projections to 
several brain regions including the VTA (7), striatum (8) and basolateral amygdala 
(BLA) (9), and we do not yet know which one of these brain regions is involved in 
regulating anxiety-like behavior downstream of PFC Cav1.2.  The BLA is an attractive 
candidate, as its function has been shown to be regulated by the CACNA1C risk 
variant, SNP rs1006737, in neuropsychiatric disorders such as schizophrenia and 
bipolar disorder (10, 11). Furthermore, human functional imaging studies show that 
even at rest, differences in functional connectivity between the PFC and amygdala 
differ in people with high versus low anxiety levels (12). Similarly in mice, 
synchronous activity between the PFC and BLA has been found to regulate anxiety-
related behaviors (13). Moreover, optogenetic stimulation of the glutamatergic 
projections from the PFC to the BLA rescues an anxiety phenotype in a rodent model 
of depression (14). To examine if the same PFC to BLA circuitry is also involved in 
Cav1.2 mediated anxiety behavior, current studies are ongoing to map the PFC 
CaMKII projection targets, including the BLA using the AAV-FLEX-GFP virus. 
Using this method, we are further able to dissociate the projection targets of CaMKII 
neurons from the distinct subregions of the PFC, the infralimbic (IL) and prelimbic 
(PrL) cortices, which not only have different functions, but also have different 
projections (15).  
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In chapter two, I describe the role of Cav1.2 in depressive-like behavior. I first 
show that Cav1.2 and not Cav1.3, specifically in the PFC and not the hippocampus 
(HPC) results in an anti-depressive behavior. This anti-depressive phenotype was also 
present in Cav1.2 HET mice. Within the PFC, I showed that Cav1.2 in the excitatory 
glutamatergic neurons do not modulate depressive behavior, suggesting a role for 
Cav1.2 in inhibitory interneurons of the PFC, contrary to the relevant cell type 
involved in anxiety-like behavior (Figure 1). A significant decrease in REDD1, a 
molecule previously associated with depression in humans and in rodent models was 
identified in the PFC of the HETs. Importantly, viral overexpression of REDD1 
reversed the higher sucrose preference phenotype in HETs, confirming that REDD1, 
downstream of Cav1.2, modulates depressive like behavior.  
Experiments are currently ongoing to explore the potential molecular targets 
downstream of REDD1. One promising target is the family of Forkhead Box, Class O 
transcription factors (FoxO), which have been shown to be involved in emotional 
behavior (16)(Polter et al., 2008). Specifically, FoxO1 has been associated with 
anxiety behaviors, whereas FoxO3a has been associated with antidepressive behavior 
(16). Importantly, FoxOs are regulated by REDD1 as well as by downstream targets of 
REDD1, such as Akt (17). REDD1 promotes PP2A-dependent dephosphorylation of 
Akt (18), which leads to reduced phosphorylation and therefore activation of FoxO1 
and FoxO3a (19). Therefore, it is possible that the HETs, which have significantly 
decreased REDD1 in the PFC, have higher phosphorylation and activity of Akt, 
leading to increased phosphorylation, hence inhibition of FoxO1 and FoxO3a. This 
pathway is particularly intriguing given that FoxO1 KO and FoxO3a KO display an 
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anxiety phenotype and anti-depressive phenotype, respectively (16), exactly as the 
HETs.  
Our data suggest that in depression, unlike in anxiety, Cav1.2 in the inhibitory 
neurons seem to be important for regulating depressive-like behaviors. The PFC 
contains both excitatory pyramidal neurons and inhibitory non-pyramidal neurons, 
including GABAergic interneurons (20) (Figure 1). Unpublished data from our lab 
shows that Cav1.2 are present in these PFC interneurons. In HETs, a 50% reduction in 
Cav1.2 channels likely results in decreased interneuron activity, which may lead to 
decreased inhibition within the PFC, resulting in an overall increase in PFC output. In 
line with this hypothesis, Covington et al., (21) suggest that a net increase in the 
output of PFC projections neurons likely underlies the modulation of depressive-like 
behavior via optogenetic stimulation of the PFC. 
 Within the PFC, it has been shown that activation of the PrL via 
overexpression of delta fos B affects depressive like behaviors whereas activation of 
the IL produced no change in baseline emotional response (14). Therefore, it would be 
interesting to see whether Cav1.2 in the inhibitory neurons of the PrL control the 
output of the PrL to regulate depressive like behavior. This leads to another question 
on a circuitry level: what is the projection target of the PFC that regulates depressive 
behavior? Optogenetic stimulation of the excitatory projections neurons from the PFC 
to the NAc has been shown to affect sucrose preference in a mouse model of 
depression (14) suggesting that NAc is a promising target. Furthermore, NAc is one of 
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the major projection sites of the PrL, but not the IL (15), further strengthening the 
argument for the involvement of the PrL to NAc pathway.   
In chapter three, I describe the role of Cav1.2 in adult hippocampal 
neurogenesis (HPC NG), a process that has been implicated in neuropsychiatric 
disorders (22). I first showed that forebrain-cacna1c cKO, which show an anxiety-like 
phenotype, show a significant deficit in adult HPC NG. I proposed that it is likely the 
Cav1.2 in the HPC that is responsible for this deficit as virus-mediated focal knockout 
of Cav1.2 in the HPC was sufficient to produce a significant deficit in adult HPC NG. 
Furthermore, I showed that the deficit in adult HPC NG of forebrain-cacna1c cKO 
does not affect HPC size and is due to decreased survival of new born neurons rather 
than a decrease in proliferation and is not due to differences in corticosterone levels.  I 
treated the forebrain-cacna1c cKO with P7C3-A20, a pro-neurogenic compound 
shown to increase survival of adult born neural progenitor cells in other mouse models 
with adult HPC NG deficits (23) and found that P7C3-A20 rescues the adult HPC NG 
deficit in forebrain-cacna1c cKO via a BDNF independent mechanism.  
Since the forebrain-cacna1c cKO have an anxiety phenotype, as well as a 
deficit in adult HPC NG, and we have shown that P7C3-A20 rescues this deficit in 
adult HPC NG, it would be worthwhile to test whether P7C3-A20 also rescues the 
anxiety phenotype. In another mouse model that also showed deficits in adult HPC 
NG, P7C3-A20 showed concomitant adult HPC NG and depressive phenotype rescue 
(24).  
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However, it is possible that P7C3-A20 may not affect anxiety, despite its 
effects on increasing adult HPC NG in forebrain-cacna1c cKO, especially given that 
focal KO of Cav1.2 in the HPC, which also results in decreased adult HPC NG, 
showed no anxiety phenotype. If this is the case, it would be interesting to test other 
behaviors that have been more heavily and reliably shown to be regulated by adult 
HPC NG, such as pattern separation (25). Pattern separation is a more subtle version 
of contextual fear conditioning wherein animals are required to differentiate between 
two similar yet distinct environments in a fear conditioning paradigm (25). This task is 
relevant to neuropsychiatric disorders such as post traumatic disorder (PTSD), in 
which people are unable to distinguish a previously traumatic scenario from a similar 
yet distinct, and non-traumatic scenario. Unpublished data from our lab show that the 
forebrain-cacna1c cKO do not show impairments in other hippocampus-dependent 
tasks such as the classic Morris Water maze, contextual fear conditioning or the 
acquisition of cocaine conditioned place preference. Therefore, it would be interesting 
to explore whether the forebrain-cacna1c cKO show a deficit in this more discrete 
dentate gyrus/ adult HPC NG dependent pattern separation task as a result of their 
deficit in adult HPC NG, and whether P7C3-A20 affects this behavior.  
If the rescue in adult HPC NG via P7C3-A20 is found to have functional 
relevance by showing a behavioral rescue in the forebrain-cacna1c cKO, the next 
experimental question to be answered would be, what are the molecular mechanisms 
that regulate the rescue of adult HPC NG?  Unpublished data from our lab show that 
several molecules known to be involved in adult HPC NG are not only expressed at 
lower levels in the HPC of forebrain-cacna1c cKO, but are also rescued by P7C3-A20 
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treatment. One such molecule of particular interest is p11, or S100-a10. p11 is present 
in the granule cells of the HPC (26), and has been shown to be required for the 
neurogenic effect of fluoxetine (26). Furthermore, decreased p11 mRNA and protein 
have been described in human depressed patients as well as in animal models of 
depression (27). BDNF increases p11 mRNA and BDNF KO mice have lower p11 
mRNA and protein (28), similar to the forebrain-cacna1c cKO that show lower BDNF 
protein as well as lower p11 mRNA in the HPC. The importance of BDNF in adult 
HPC NG is well established (29); BDNF is necessary for numerous modes of adult 
HPC NG enhancement such as exercise (30) and environmental enrichment (31) and 
BDNF on its own is enough to increase adult HPC NG (29). Therefore, it is plausible 
that BDNF may play a role in the deficit in adult HPC NG seen in the forebrain-
cacna1c cKO, and that P7C3-A20 rescues this deficit via affecting p11 directly. This 
hypothesis may be tested by virus-mediated overexpression of p11 in the HPC of 
forebrain-cacna1c cKO to see if the deficit in adult HPC NG is rescued. 
Adult HPC NG has been proposed to be involved in memory, in particular, 
HPC-dependent contextual memory (30, 32). Moreover, not only is there high co-
morbidity between anxiety and depression and drug addiction, but carriers of the 
CACNA1C SNP display abnormal reward response (33). Therefore, in chapter four, I 
explored the role of Cav1.2 in the maintenance of long-term cocaine-context 
association memory. I found that focal knockout of Cav1.2 in the HPC results in the 
persistent maintenance of cocaine-context association memory, even after long-term 
forced abstinence, or withdrawal, from cocaine. I showed that the maintenance of the 
cocaine context association memory is due to potentially increased glutamatergic 
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output from the HPC to the brain’s reward center, the NAc (Figure 1), and to the 
preferential activation of the CaMKII pathway, and not the PP2B pathway, in the 
NAc.  
All of the data presented above were collected after 30 days of cocaine 
withdrawal. It is difficult to pinpoint therefore, exactly what mechanisms the 
preferential activation of the CaMKII pathway regulates. For example, is the CaMKII 
pathway required for the reconsolidation of the cocaine-context association memory? 
Or is it required for the recall of the cocaine-context association memory? One way to 
answer these questions is to implant guide cannulae into the NAc of wildtype mice, 
and infuse CaMKII activator either during the duration of the withdrawal period or 
right before the WD30 test to address whether the preferential activation of the 
CaMKII pathway is required during these distinct processes of reconsolidation versus 
recall. Another interesting follow up experiment would be to test whether the CaMKII 
pathway is preferentially activated over the PP2B pathway in the NAc immediately 
after the acquisition test, an early withdrawal time point. The same pathways should 
be studied in the HPC of the same mice to see if initially, similar molecular processes 
occur in the HPC, which then transfers to the NAc following long-term withdrawal.  
At WD30 time point, another interesting question to be asked is whether the 
NMDAR in the NAc are upregulated. I hypothesize that the glutamatergic output from 
the HPC is increased in the HPC Cav1.2 KO; hence, I would predict that there would 
be an upregulation in the NMDAR in the NAc at this timepoint. Also, since there is a 
significant change in phosphoGluA1 S831, it would be interesting to test the GluA1 
S831 phospho-mutants to address whether this specific post-translational modification 
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is a required molecular event. The GluA1 S831 in these mice are not able to be 
phosphorylated (34). Therefore, one could knockout Cav1.2 in the HPC of these mice 
then test them in the long-term WD CPP task to address whether phosphorylation of 
S831 of GluA1 is required for Cav1.2 regulated maintenance of cocaine-context 
association memory.  
 Finally, although the molecular findings reported in this dissertation is likely 
to be specific to cocaine reward memories since the changes occur in the NAc, one 
could test whether KO of Cav1.2 in the HPC affects long-term recall of other types of 
HPC dependent memory such as Morris Water maze, or object location test or even 
conditioned aversion.  
 
In conclusion, in this dissertation, I report my findings on the role of Cav1.2 in 
specific brain regions and cell types in anxiety and depressive like behaviors. I report 
that Cav1.2 in the excitatory glutamatergic neurons of the PFC regulates anxiety-like 
behaviors, whereas Cav1.2 in non-glutamatergic neurons of the PFC regulates 
depressive-like behaviors (Figure 1). Furthermore, I report that Cav1.2 in the 
excitatory glutamatergic neurons of the forebrain are required for the survival of adult 
born neural progenitor cells, and that KO of HPC Cav1.2 even in adulthood, is 
sufficient to cause a deficit in adult HPC NG. Finally, I describe a role of HPC Cav1.2 
in regulating long-term cocaine context-association memories via the CaMKII 
pathway. These novel findings are significant to the field of LTCCs, as although much 
work has been done to investigate the molecular mechanisms of Cav1.2, not nearly as 
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much has been accomplished in describing the role of Cav1.2 in behavioral tasks that 
are translatable to human neuropsychiatric disorders. The findings I report in this 
dissertation lay the groundwork for various exciting future experiments that will 
further elucidate the role of Cav1.2 in neuropsychiatric disorders. 
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